Public Assessment Report

Decentralised Procedure

RIBAVIRIN 200MG CAPSULES

UK/H/3127/001/DC
UK Licence No: PL 17780/0439

WINTHROP PHARMACEUTICALS UK LIMITED
LAY SUMMARY

On 7th October 2011, the UK granted Winthrop Pharmaceuticals UK Limited a Marketing Authorisation (licence) for Ribavirin 200mg Capsules.

Ribavirin 200mg Capsules contain the active ingredient ribavirin. Ribavirin 200mg Capsules is an antiviral medication. It is used to stop the multiplication of many types of viruses, including hepatitis C virus. Ribavirin must not be used alone. It must be used together with peginterferon alfa-2b or interferon alfa-2b.

Previously untreated patients

The combination of ribavirin with peginterferon alfa-2b or interferon alfa-2b is used to treat patients 3 years of age and older who have chronic hepatitis C (HCV) infection.

The combination of ribavirin with peginterferon alfa-2b is also used to treat patients 18 years of age or older who have chronic hepatitis C, including patients who are co-infected with clinically stable human immunodeficiency virus (HIV).

Previously treated adult patients

The combination of ribavirin with interferon alfa-2b is used to treat adult patients with chronic hepatitis C, who have previously responded to a treatment with an alpha interferon alone, but whose condition has returned.

The combination therapy of ribavirin with peginterferon alfa-2b is used to treat adult patients with chronic hepatitis C who have previously responded to treatment with an alpha interferon (pegylated or non-pegylated), alone or in combination therapy with ribavirin, but whose condition has returned.

The combination therapy of ribavirin with peginterferon alfa-2b is used to treat adult patients with chronic hepatitis C who have not responded to previous treatment with an alpha interferon (pegylated or non-pegylated), alone or in combination therapy with ribavirin.

No new or unexpected safety concerns arose from this application and it was, therefore, judged that the benefits of taking Ribavirin 200mg Capsules outweigh the risks; hence this Marketing Authorisation has been granted.
TABLE OF CONTENTS

Module 1: Information about initial procedure  Page 4
Module 2: Summary of Product Characteristics  Page 5
Module 3: Product Information Leaflets  Page 32
Module 4: Labelling  Page 43
Module 5: Scientific Discussion  Page 53
   1 Introduction
   2 Quality aspects
   3 Non-clinical aspects
   4 Clinical aspects
   5 Overall conclusions
Module 6: Steps taken after initial procedure  Not applicable
## Module 1

<table>
<thead>
<tr>
<th><strong>Product Name</strong></th>
<th>Ribavirin 200mg Capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Application</strong></td>
<td>Generic application, Article 10.1</td>
</tr>
<tr>
<td><strong>Active Substance</strong></td>
<td>Ribavirin</td>
</tr>
<tr>
<td><strong>Form</strong></td>
<td>Capsules</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>200mg</td>
</tr>
</tbody>
</table>
| **MA Holder** | Winthrop Pharmaceuticals UK limited  
One Onslow Street  
Guildford  
Surrey  
GU1 4YS  
United Kingdom |
| **Reference Member State (RMS)** | UK |
| **Concerned Member States (CMS)** | Germany (DE), France (FR) |
| **Procedure Number** | UK/H/3127/001/DC |
| **End of Procedure** | Day 180: 19th September 2011 |
Module 2
Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT
Ribavirin 200mg Capsules

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains 200mg of ribavirin.
Excipient: each hard capsule contains 45 mg of lactose monohydrate.
For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Hard capsule
White/white, size ‘1’ hard gelatin capsules filled with white to off-white granular powder and
imprinted with ‘E’ on white cap and ‘81’ on white body with black ink.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Ribavirin 200mg Capsules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in
adults, children 3 years of age and older and adolescents and must only be used as part of a
combination regimen with peginterferon alfa-2b or interferon alfa-2b. Ribavirin 200mg Capsules
monotherapy must not be used.

There is no safety or efficacy information on the use of Ribavirin 200mg Capsules with other forms of
interferon (i.e., not alfa-2b).

Naïve patients
Adult patients: Ribavirin 200mg Capsules is indicated, in combination with interferon alfa-2b or
peginterferon alfa-2b, for the treatment of adult patients with chronic hepatitis C, not previously
treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive
for hepatitis C viral ribonucleic acid (HCV-RNA). In combination with peginterferon alfa-2b also
patients with compensated cirrhosis and/or clinically stable HIV co-infection are included (see section
4.4).

Children 3 years of age and older and adolescents: Ribavirin 200mg Capsules is indicated, in a
combination regimen with peginterferon alfa-2b or interferon alfa-2b, for the treatment of children 3
years of age and older and adolescents, who have chronic hepatitis C, not previously treated, without
liver decompensation, and who are positive for HCV-RNA.
When deciding to not to defer treatment until adulthood, it is important to consider that the
combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain.
The decision to treat should be made on a case by case basis (see section 4.4).

Previously treated patients
Adult patients: Ribavirin 200mg Capsules is indicated, in combination with interferon alfa-2b, for the
treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation
of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed.
Ribavirin 200mg Capsules is indicated, in combination with peginterferon alfa-2b, for the treatment of
adult patients with chronic hepatitis C who have failed previous treatment with interferon alpha
(pegylated or non-pegylated) alone or in combination with ribavirin (see section 5.1).

4.2 Posology and method of administration
Treatment should be initiated, and monitored, by a physician experienced in the management of
chronic hepatitis C.

Ribavirin 200mg Capsules must be used in combination with either peginterferon alfa-2b or interferon
alfa-2b.

Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics
(SPC) for prescribing information particular to that product.
**Dose to be administered**
The dose of Ribavirin 200mg Capsules is based on patient body weight. Ribavirin 200mg Capsules are to be administered orally each day in two divided doses (morning and evening) with food.

**Adult patients:**
The dose of ribavirin is based on patient body weight (*Table 1*).
Ribavirin 200mg Capsules must be used in combination with either peginterferon alfa-2b (1.5 micrograms/kg/week) or interferon alfa-2b (3 million international units [MIU] three times a week). The choice of combination regimen is based on the characteristics of the patient. The regimen administered should be selected based on the anticipated efficacy and safety of the combination treatment for an individual patient (see section 5.1).

**Table 1.** Ribavirin 200mg Capsules dose based on body weight for HCV monoinfected or HCV/HIV co-infected patients and whatever the genotype

<table>
<thead>
<tr>
<th>Patient weight (kg)</th>
<th>Daily ribavirin dose</th>
<th>Number of 200 mg capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 65</td>
<td>800 mg</td>
<td>4(^a)</td>
</tr>
<tr>
<td>65 – 80</td>
<td>1.000 mg</td>
<td>5(^b)</td>
</tr>
<tr>
<td>81 - 105</td>
<td>1.200 mg</td>
<td>6(^c)</td>
</tr>
<tr>
<td>&gt; 105</td>
<td>1.400 mg</td>
<td>7(^d)</td>
</tr>
</tbody>
</table>

\(^a\): 2 morning, 2 evening  
\(^b\): 2 morning, 3 evening  
\(^c\): 3 morning, 3 evening  
\(^d\): 3 morning, 4 evening

Ribavirin 200mg Capsules in combination with peginterferon alfa-2b:

*Duration of treatment – Naive patients*

*Predictability of sustained virological response:* Patients infected with virus genotype 1 who fail to achieve undetectable HCV-RNA or demonstrate adequate virological response at week 4 or 12 are highly unlikely to become sustained virological responders and should be evaluated for discontinuation (see also section 5.1).

**Genotype 1:**
- Patients who have undetectable HCV-RNA at treatment week 12, treatment should be continued for another nine month period (i.e., a total of 48 weeks).
- Patients with detectable but \(\geq 2\) log decrease in HCV-RNA level from baseline at treatment week 12 should be reassessed at treatment week 24 and, if HCV-RNA is undetectable, they should continue with full course of therapy (i.e., a total of 48 weeks). However, if HCV-RNA is still detectable at treatment week 24, discontinuation of therapy should be considered.
- In the subset of patients with genotype 1 infection and low viral load (< 600,000 IU/ml) who become HCV-RNA negative at treatment week 4 and remain HCV-RNA negative at week 24, the treatment could either be stopped after this 24 week treatment course or pursued for an additional 24 weeks (i.e. overall 48 weeks treatment duration). However, an overall 24 weeks treatment duration may be associated with a higher risk of relapse than a 48 weeks treatment duration (see section 5.1).
- **Genotype 2 or 3:** It is recommended that all patients be treated for 24 weeks, except for HCV/HIV co-infected patients who should receive 48 weeks of treatment.
- **Genotype 4:** In general, patients infected with genotype 4 are considered harder to treat and limited study data (n=66) indicate they are compatible with a duration of treatment as for genotype 1.

*Duration of treatment - HCV/HIV co-infected patients*
The recommended duration of Ribavirin 200mg Capsules weight-based dosing (see *Table 1*) for HCV/HIV co-infected patients is 48 weeks, regardless of genotype.

*Predictability of response and non-response in HCV/HIV Co-infection*
Early virological response by week 12, defined as a 2 log viral load decrease or undetectable levels of HCV-RNA, has been shown to be predictive for sustained response. The negative predictive value for sustained response in HCV/HIV co-infected patients treated with Ribavirin 200mg Capsules in combination with peginterferon alfa-2b was 99% (67/68; Study 1) (see section 5.1). A positive
predictive value of 50% (52/104; Study 1) was observed for HCV/HIV co-infected patients receiving combination therapy.

**Duration of treatment - Retreatment**

Predictability of sustained virological response: All patients, irrespective of genotype, who have demonstrated serum HCV-RNA below the limits of detection at week 12 should receive 48 weeks of therapy. Retreated patients who fail to achieve virological response (i.e. HCV-RNA below the limits of detection) at week 12 are unlikely to become sustained virological responders after 48 weeks of therapy (see also section 5.1).

Retreatment duration greater than 48 weeks in non-responder patients with genotype 1 has not been studied with pegylated interferon alfa-2b and ribavirin combination therapy.

Ribavirin 200mg Capsules in combination with interferon alfa-2b:

**Duration of treatment:**

Based on the results of clinical trials, it is recommended that patients be treated for at least six months. During those clinical trials in which patients were treated for one year, patients who failed to show a virological response after six months of treatment (HCV-RNA below lower limit of detection) were unlikely to become sustained virological responders (HCV-RNA below lower limit of detection six months after withdrawal of treatment).

- **Genotype 1:** Treatment should be continued for another six months period (i.e., a total of one year) in patients who exhibit negative HCV-RNA after six months of treatment.
- **Genotypes Non-1:** The decision to extend therapy to one year in patients with negative HCV-RNA after six months of treatment should be based on other prognostic factors (e.g., age > 40 years, male gender, bridging fibrosis).

**Children 3 years of age and older and adolescents:**

Note: For patients who weigh < 47 kg, or are unable to swallow capsules, please refer to SmPC for pediatric formulation of ribavirin.

Dosing for children and adolescent patients is determined by body weight for Ribavirin 200mg Capsules and by body surface area for peginterferon alfa-2b and interferon alfa-2b.

**Dose to be administered for the combination therapy with peginterferon alfa-2b:**

The recommended dose of peginterferon alfa-2b is 60 microgram/m²/week subcutaneously in combination with Ribavirin 200mg Capsules 15 mg/kg/day (Table 2).

**Dose to be administered for the combination therapy with interferon alfa-2b:**

In clinical studies performed in this population ribavirin and interferon alfa-2b were used in doses of 15 mg/kg/day and 3 million international units (MIU)/m² three times a week respectively (Table 2).

<table>
<thead>
<tr>
<th>Patient weight (kg)</th>
<th>Daily Ribavirin 200mg Capsules dose</th>
<th>Number of 200 mg capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>47 - 49</td>
<td>600 mg</td>
<td>3 capsules a</td>
</tr>
<tr>
<td>50 - 65</td>
<td>800 mg</td>
<td>4 capsules b</td>
</tr>
<tr>
<td>&gt; 65</td>
<td>Refer to adult dosing table (Table 1)</td>
<td></td>
</tr>
</tbody>
</table>

a:1 capsule morning, 2 evening  
b:2 capsules morning, 2 evening

**Duration of treatment in children and adolescents**

- **Genotype 1:** The recommended duration of treatment is 1 year. By extrapolation from clinical data on combination therapy with standard interferon in paediatric patients (negative predictive value 96% for interferon alfa-2b/ribavirin), patients who fail to achieve virological response at 12 weeks are highly unlikely to become sustained virological responders. Therefore, it is recommended that children and adolescent patients receiving interferon alfa-2b (pegylated or non-pegylated)/ribavirin combination be discontinued from therapy if their week 12 HCV-RNA dropped < 2 log_{10} compared to pretreatment, or if they have detectable HCV-RNA at treatment week 24.

- **Genotype 2 or 3:** The recommended duration of treatment is 24 weeks.

- **Genotype 4:** Only 5 children and adolescents with Genotype 4 were treated in the peginterferon alfa-2b/ribavirin clinical trial. The recommended duration of treatment is 1 year. It is recommended that children and adolescent patients receiving peginterferon alfa-2b/ribavirin combination be discontinued from therapy if their week 12 HCV-RNA dropped < 2 log_{10} compared to pretreatment, or if they have detectable HCV-RNA at treatment week 24.
Dose modification for all patients

If severe adverse reactions or laboratory abnormalities develop during therapy with Ribavirin 200mg Capsules and peginterferon alfa-2b or interferon alfa-2b, modify the dosages of each product if appropriate, until the adverse reactions abate. Guidelines were developed in clinical trials for dose modification (see Dosage modification guidelines, Table 3). As adherence might be of importance for outcome of therapy, the dose should be kept as close as possible to the recommended standard dose. The potential negative impact of ribavirin dose reduction on efficacy results could not be ruled out.

Table 3  Dosage modification guidelines based on laboratory parameters

<table>
<thead>
<tr>
<th>Laboratory values</th>
<th>Reduce only Ribavirin 200mg Capsules daily dose (see note 1) if:</th>
<th>Reduce only peginterferon alfa-2b or interferon alfa-2b dose (see note 2) if:</th>
<th>Discontinue combination therapy when the below test value is reported:**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin</td>
<td>&lt; 10 g/dl -</td>
<td>&lt; 12 g/dl after 4 weeks of dose reduction</td>
<td></td>
</tr>
<tr>
<td>Adults: Haemoglobin in: patients with history of stable cardiac disease</td>
<td>≥ 2 g/dl decrease in haemoglobin during any 4 week period during treatment (permanent dose reduction)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children and adolescents: not applicable (see section 4.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocytes</td>
<td>-</td>
<td>&lt; 25 x 10^9/l (adults)</td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>-</td>
<td>&lt; 25 x 10^9/l (adults)</td>
<td></td>
</tr>
<tr>
<td>Platelets</td>
<td>&lt; 1.0 x 10^9/l</td>
<td>&lt; 25 x 10^9/l (adults)</td>
<td></td>
</tr>
<tr>
<td>Bilirubin – Direct</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilirubin – Indirect</td>
<td>&gt; 5 mg/dl</td>
<td>&gt; 4 mg/dl (adults)</td>
<td></td>
</tr>
<tr>
<td>Serum Creatinine</td>
<td>-</td>
<td>&gt; 5 mg/dl (for &gt; 4 weeks) (children and adolescents treated with interferon alfa-2b), or &gt; 4 mg/dl (for &gt; 4 weeks) (children and adolescents treated with peginterferon alfa-2b))</td>
<td></td>
</tr>
<tr>
<td>Creatinine Clearance</td>
<td>-</td>
<td>Discontinue Ribavirin 200mg Capsules if CrCl &lt; 50 ml/minute</td>
<td></td>
</tr>
<tr>
<td>Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)</td>
<td>-</td>
<td>2 x baseline and &gt; 10 x ULN* or 2 x baseline and &gt; 10 x ULN*</td>
<td></td>
</tr>
</tbody>
</table>

* Upper limit of normal

** Refer to the SPC for pegylated interferon alfa-2b and interferon alfa-2b for dose modification and discontinuation.

Note 1:
In adult patients, 1st dose reduction of Ribavirin 200mg Capsules is by 200 mg/day (except in patients receiving the 1.400 mg, dose reduction should be by 400 mg/day). If needed, 2nd dose reduction of Ribavirin 200mg Capsules is by an additional 200 mg/day. Patients whose dose of Ribavirin 200mg Capsules is reduced to 600 mg daily receive one 200 mg capsule in the morning and two 200 mg capsules in the evening.
In children and adolescent patients treated with Ribavirin 200mg Capsules plus peginterferon alfa-2b, 1st dose reduction of Ribavirin 200mg Capsules is to 12 mg/kg/day, 2nd dose reduction of Ribavirin 200mg Capsules is to 8 mg/kg/day.

In children and adolescent patients treated with Ribavirin 200mg Capsules plus interferon alfa-2b, reduce Ribavirin 200mg Capsules dose to 7.5 mg/kg/day.

**Note 2:**
In adult patients treated with Ribavirin 200mg Capsules plus peginterferon alfa-2b, 1st dose reduction of peginterferon alfa-2b is to 1 μg/kg/week. If needed, 2nd dose reduction of peginterferon alfa-2b is to 0.5 μg/kg/week.

In children and adolescent patients treated with Ribavirin 200mg Capsules plus peginterferon alfa-2b, 1st dose reduction of peginterferon alfa-2b is to 40 μg/m²/week, 2nd dose reduction of peginterferon alfa-2b is to 20 μg/m²/week.

In adult patients and children and adolescent patients treated with Ribavirin 200mg Capsules plus interferon alfa-2b, reduce the interferon alfa-2b dose by one-half dose.

**Special populations**

*Use in renal impairment:* The pharmacokinetics of ribavirin are altered in patients with renal dysfunction due to reduction of apparent creatinine clearance in these patients (see section 5.2). Therefore, it is recommended that renal function be evaluated in all patients prior to initiation of Ribavirin 200mg Capsules. Patients with creatinine clearance < 50ml/minute must not be treated with ribavirin (see section 4.3). Subjects with impaired renal function should be more carefully monitored with respect to the development of anaemia. If serum creatinine rises to > 2.0mg/dl (Table 3), ribavirin and peginterferon alfa-2b/interferon alfa-2b must be discontinued.

*Use in hepatic impairment:* No pharmacokinetic interaction appears between ribavirin and hepatic function (see section 5.2). Therefore, no dose adjustment of Ribavirin 200mg Capsules is required in patients with hepatic impairment. The use of ribavirin is contraindicated in patients with severe hepatic impairment or decompensated cirrhosis (see section 4.3).

*Use in the elderly (≥ 65 years of age):* There does not appear to be a significant age-related effect on the pharmacokinetics of ribavirin. However, as in younger patients, renal function must be determined prior to administration of Ribavirin 200mg Capsules (see section 5.2).

*Use in patients under the age of 18 years:* Ribavirin 200mg Capsules may be used in combination with peginterferon alfa-2b or interferon alfa-2b in children 3 years of age and older and adolescents. The selection of formulation is based on individual characteristics of the patient. Safety and effectiveness of ribavirin with other forms of interferon (i.e. not alfa-2b) in these patients have not been evaluated.

*Patients co-infected with HCV/HIV:* Patients taking nucleoside reverse transcriptase inhibitor (NRTI) treatment in association with ribavirin and interferon alfa-2b or peginterferon alfa-2b may be at increased risk of mitochondrial toxicity, lactic acidosis and hepatic decompensation (see section 4.4). Please refer also to the relevant product information for antiretroviral medicinal products.

### 4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients.
- Pregnant women (see sections 4.4, 4.6 and 5.3). Ribavirin 200mg Capsules must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
- Lactation.
- A history of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease, in the previous six months (see section 4.4).
- Patients with severe, debilitating medical conditions.
- Patients with chronic renal failure, patients with creatinine clearance < 50 ml/minute and/or on haemodialysis.
- Severe hepatic impairment (Child-Pugh Classification B or C) or decompensated cirrhosis of the liver.
- Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).
- Initiation of peginterferon alfa-2b is contraindicated in HCV/HIV patients with cirrhosis and a Child-Pugh score ≥ 6.
- Children and adolescents:
• Existence of or history of severe psychiatric condition, particularly severe depression, suicidal ideation, or suicide attempt.

Because of co-administration with peginterferon alfa-2b or interferon alfa-2b:
Autoimmune hepatitis; or history of autoimmune disease.

4.4 Special warnings and precautions for use

Psychiatric and Central Nervous System (CNS):
Severe CNS effects, particularly depression, suicidal ideation and attempted suicide have been observed in some patients during ribavirin combination therapy with peginterferon alfa-2b or interferon alfa-2b, and even after treatment discontinuation mainly during the 6-month follow-up period. Among children and adolescents, treated with ribavirin in combination with interferon alfa-2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4% versus 1%) during treatment and during the 6-month follow-up after treatment. As in adult patients, children and adolescents experienced other psychiatric adverse reactions (e.g., depression, emotional lability, and somnolence). Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania, confusion and alterations of mental status have been observed with alpha interferons. Patients should be closely monitored for any signs or symptoms of psychiatric disorders. If such symptoms appear, the potential seriousness of these undesirable effects must be borne in mind by the prescribing physician and the need for adequate therapeutic management should be considered. If psychiatric symptoms persist or worsen, or suicidal ideation is identified, it is recommended that treatment with ribavirin and peginterferon alfa-2b or interferon alfa-2b be discontinued, and the patient followed, with psychiatric intervention as appropriate.

Patients with existence or history of severe psychiatric conditions: If treatment with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b is judged necessary in adult patients with existence or history of severe psychiatric conditions, this should only be initiated after having ensured appropriate individualised diagnostic and therapeutic management of the psychiatric condition. The use of ribavirin and interferon alfa-2b or peginterferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).

Growth and development (children and adolescents):
During the course of interferon (standard and pegylated)/ribavirin therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common (see sections 4.8 and 5.1). The longer term data available in children treated with the combination therapy with standard interferon/ribavirin are also indicative of substantial growth retardation (> 15 percentile decrease in height percentile as compared to baseline) in 21% of children despite being off treatment for more than 5 years.

Case by case benefit/risk assessment in children:
The expected benefit of treatment should be carefully weighed against the safety findings observed for children and adolescents in the clinical trials (see sections 4.8 and 5.1).

• It is important to consider that the combination therapy induced a growth inhibition, the reversibility of which is uncertain.
• This risk should be weighed against the disease characteristics of the child, such as evidence of disease progression (notably fibrosis), co-morbidities that may negatively influence the disease progression (such as HIV-co-infection), as well as prognostic factors of response (HCV genotype and viral load).

Whenever possible the child should be treated after the pubertal growth spurt, in order to reduce the risk of growth inhibition. There are no data on long term effects on sexual maturation.

Based on results of clinical trials, the use of ribavirin as monotherapy is not effective and ribavirin must not be used alone. The safety and efficacy of this combination have been established only using ribavirin capsules together with peginterferon alfa-2b or interferon alfa-2b solution for injection.

All patients in selected chronic hepatitis C studies had a liver biopsy before inclusion, but in certain cases (i.e. patients with genotype 2 and 3), treatment may be possible without histological confirmation. Current treatment guidelines should be consulted as to whether a liver biopsy is needed prior to commencing treatment.
Haemolysis: A decrease in haemoglobin levels to < 10 g/dl was observed in up to 14% of adult patients and 7% of children and adolescents treated with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials. Although ribavirin has no direct cardiovascular effects, anaemia associated with ribavirin may result in deterioration of cardiac function, or exacerbation of the symptoms of coronary disease, or both. Thus, Ribavirin 200mg Capsules must be administered with caution to patients with pre-existing cardiac disease (see section 4.3). Cardiac status must be assessed before start of therapy and monitored clinically during therapy; if any deterioration occurs, therapy must be stopped (see section 4.2).

Cardiovascular: Adult patients with a history of congestive heart failure, myocardial infarction and/or previous or current arrhythmic disorders must be closely monitored. It is recommended that those patients who have pre-existing cardiac abnormalities have electrocardiograms taken prior to and during the course of treatment. Cardiac arrhythmias (primarily supraventricular) usually respond to conventional therapy but may require discontinuation of therapy. There are no data in children or adolescents with a history of cardiac disease.

Acute hypersensitivity: If an acute hypersensitivity reaction (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) develops, Ribavirin 200mg Capsules must be discontinued immediately and appropriate medical therapy instituted. Transient rashes do not necessitate interruption of treatment.

Ocular changes: Ribavirin is used in combination therapy with alpha interferons. Retinopathy including retinal haemorrhages, retinal exudates, papilloedema, optic neuropathy and retinal artery or vein occlusion which may result in loss of vision have been reported in rare instances with combination therapy with alpha interferons. All patients should have a baseline eye examination. Any patient complaining of decrease or loss of vision must have a prompt and complete eye examination. Patients with preexisting ophthalmologic disorders (e.g., diabetic or hypertensive retinopathy) should receive periodic ophthalmologic exams during combination therapy with alpha interferons. Combination therapy with alpha interferons should be discontinued in patients who develop new or worsening ophthalmologic disorders.

Liver function: Any patient developing significant liver function abnormalities during treatment must be monitored closely. Discontinue treatment in patients who develop prolongation of coagulation markers which might indicate liver decompensation.

Potential to exacerbate immunosuppression: Pancytopenia and bone marrow suppression have been reported in the literature to occur within 3 to 7 weeks after the administration of a peginterferon and ribavirin concomitantly with azathioprine. This myelotoxicity was reversible within 4 to 6 weeks upon withdrawal of HCV antiviral therapy and concomitant azathioprine and did not recur upon reintroduction of other treatment alone (see section 4.5).

Thyroid supplemental monitoring specific for children and adolescents: Approximately 12 to 21% of children treated with ribavirin and interferon alfa-2b (pegylated and non-pegylated) developed increase in thyroid stimulating hormone (TSH). Another approximately 4% had a transient decrease below the lower limit of normal. Prior to initiation of interferon alfa-2b therapy, TSH levels must be evaluated and any thyroid abnormality detected at that time must be treated with conventional therapy. Interferon alfa-2b (pegylated and non-pegylated) therapy may be initiated if TSH levels can be maintained in the normal range by medication. Thyroid dysfunction during treatment with ribavirin and interferon alfa-2b and during treatment with ribavirin and peginterferon alfa-2b has been observed. If thyroid abnormalities are detected, the patient's thyroid status should be evaluated and treated as clinically appropriate. Children and adolescents should be monitored every 3 months for evidence of thyroid dysfunction (e.g. TSH).

HCV/HIV Co-infection:
Mitochondrial toxicity and lactic acidosis: Caution should be taken in HIV-positive subjects co-infected with HCV who receive nucleoside reverse transcriptase inhibitor (NRTI) treatment (especially ddi and d4T) and associated interferon alfa-2b/ribavirin treatment. In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when ribavirin is administered. In particular:
- co-administration of ribavirin and didanosine is not recommended due to the risk of mitochondrial toxicity (see section 4.5).
• co-administration of ribavirin and stavudine should be avoided to limit the risk of overlapping mitochondrial toxicity.

Hepatic decompensation in HCV/HIV co-infected patients with advanced cirrhosis:
Co-infected patients with advanced cirrhosis receiving highly active anti-retroviral therapy (HAART) may be at increased risk of hepatic decompensation and death. Adding treatment with alfa interferons alone or in combination with ribavirin may increase the risk in this patient subset. Other baseline factors in co-infected patients that may be associated with a higher risk of hepatic decompensation include treatment with didanosine and elevated bilirubin serum concentrations.

Co-infected patients receiving both antiretroviral (ARV) and anti-hepatitis treatment should be closely monitored, assessing their Child-Pugh score during treatment. Patients progressing to hepatic decompensation should have their anti-hepatitis treatment immediately discontinued and the ARV treatment reassessed.

Haematological abnormalities in HCV/HIV co-infected patients:
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients. Although, the majority of them could be managed by dose reduction, close monitoring of haematological parameters should be undertaken in this population of patients (see section 4.2 and below "Laboratory tests" and section 4.8).

Patients treated with ribavirin and zidovudine are at increased risk of developing anaemia; therefore, the concomitant use of ribavirin with zidovudine is not recommended (see section 4.5).

Patients with low CD4 counts:
In patients co-infected with HCV/HIV, limited efficacy and safety data (N = 25) are available in subjects with CD4 counts less than 200 cells/microlitre. Caution is therefore warranted in the treatment of patients with low CD4 counts.

Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin and peginterferon alfa-2b.

Dental and periodontal disorders: Dental and periodontal disorders, which may lead to loss of teeth, have been reported in patients receiving ribavirin and peginterferon alfa-2b or interferon alfa-2b combination therapy. In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of ribavirin and peginterferon alfa-2b or interferon alfa-2b. Patients should brush their teeth thoroughly twice daily and have regular dental examinations. In addition some patients may experience vomiting. If this reaction occurs, they should be advised to rinse out their mouth thoroughly afterwards.

Laboratory tests: Standard haematologic tests and blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) must be conducted in all patients prior to initiating therapy. Acceptable baseline values that may be considered as a guideline prior to initiation of Ribavirin 200mg Capsules therapy:

- **Haemoglobin**  
  - Adult: ≥12 g/dl (females); ≥13 g/dl (males)  
  - Children and adolescents: ≥11 g/dl (females); ≥12 g/dl (males)

- **Platelets**  
  ≥ 100,000/mm³

- **Neutrophil Count**  
  ≥ 1.500/mm³

Laboratory evaluations are to be conducted at weeks 2 and 4 of therapy, and periodically thereafter as clinically appropriate. HCV-RNA should be measured periodically during treatment (see section 4.2).

For females of childbearing potential: Female patients must have a routine pregnancy test performed monthly during treatment and for four months thereafter. Female partners of male patients must have a routine pregnancy test performed monthly during treatment and for seven months thereafter (see section 4.6).

Uric acid may increase with ribavirin due to haemolysis; therefore, the potential for development of gout must be carefully monitored in pre-disposed patients.
Use in patients with rare hereditary disorders: Each Ribavirin 200mg Capsules contains 45 mg of lactose. Patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Results of in vitro studies using both human and rat liver microsome preparations indicated no cytochrome P450 enzyme mediated metabolism of ribavirin. Ribavirin does not inhibit cytochrome P450 enzymes. There is no evidence from toxicity studies that ribavirin induces liver enzymes. Therefore, there is a minimal potential for P450 enzyme-based interactions.

Ribavirin, by having an inhibitory effect on inosine monophosphate dehydrogenase, may interfere with azathioprine metabolism possibly leading to an accumulation of 6-methylthioinosine monophosphate (6-MTIMP), which has been associated with myelotoxicity in patients treated with azathioprine. The use of pegylated alpha interferons and ribavirin concomitantly with azathioprine should be avoided. In individual cases where the benefit of administering ribavirin concomitantly with azathioprine warrants the potential risk, it is recommended that close hematologic monitoring be done during concomitant azathioprine use to identify signs of myelotoxicity, at which time treatment with these medicines should be stopped (see section 4.4).

No interaction studies have been conducted with ribavirin and other medicinal products, except for peginterferon alfa-2b, interferon alfa-2b and antacids.

Interferon alfa-2b: No pharmacokinetic interactions were noted between ribavirin and peginterferon alfa-2b or interferon alfa-2b in a multiple-dose pharmacokinetic study.

Antacid: The bioavailability of ribavirin 600 mg was decreased by co-administration with an antacid containing magnesium aluminium and simethicone; AUC<sub>trf</sub> decreased 14%. It is possible that the decreased bioavailability in this study was due to delayed transit of ribavirin or modified pH. This interaction is not considered to be clinically relevant.

Nucleoside analogs: Use of nucleoside analogs, alone or in combination with other nucleosides, has resulted in lactic acidosis. Pharmacologically, ribavirin increases phosphorylated metabolites of purine nucleosides in vitro. This activity could potentiate the risk of lactic acidosis induced by purine nucleoside analogs (e.g. didanosine or abacavir). Co-administration of ribavirin and didanosine is not recommended. Reports of mitochondrial toxicity, in particular lactic acidosis and pancreatitis, of which some fatal, have been reported (see section 4.4). The exacerbation of anaemia due to ribavirin has been reported when zidovudine is part of the regimen used to treat HIV although the exact mechanism remains to be elucidated. The concomitant use of ribavirin with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4). Consideration should be given to replacing zidovudine in a combination anti-retroviral treatment (ART) regimen if this is already established. This would be particularly important in patients with a known history of zidovudine induced anaemia. Any potential for interactions may persist for up to two months (five half-lives for ribavirin) after cessation of ribavirin therapy due to the long half-life (see section 5.2). There is no evidence that ribavirin interacts with non-nucleoside reverse transcriptase inhibitors or protease inhibitors. Conflicting findings are reported in literature on co-administration between abacavir and ribavirin. Some data suggest that HIV/HCV co-infected patients receiving abacavir-containing ART may be at risk of a lower response rate to pegylated interferon/ribavirin therapy. Caution should be exercised when both medicines are co-administered.

4.6 Fertility, Pregnancy and lactation

The use of Ribavirin 200mg Capsules is contraindicated during pregnancy.

Preclinical data:

- Fertility: In animal studies, ribavirin produced reversible effects on spermatogenesis (see section 5.3).
- Teratogenicity: Significant teratogenic and/or embryocidal potential have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted, occurring at doses as low as one twentieth of the recommended human dose (see section 5.3).
Genotoxicity: Ribavirin induces genotoxicity (see section 5.3).

Female patients: Ribavirin 200mg Capsules must not be used by females who are pregnant (see sections 4.3 and 5.3). Extreme care must be taken to avoid pregnancy in female patients (see section 5.3). Ribavirin therapy must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and their partners must each use an effective contraceptive during treatment and for four months after treatment has been concluded; routine monthly pregnancy tests must be performed during this time. If pregnancy does occur during treatment or within four months from stopping treatment, the patient must be advised of the significant teratogenic risk of ribavirin to the foetus.

Male patients and their female partners: Extreme care must be taken to avoid pregnancy in partners of male patients taking ribavirin (see sections 4.3 and 5.3). Ribavirin accumulates intracellularly and is cleared from the body very slowly. It is unknown whether the ribavirin that is contained in sperm will exert its potential teratogenic or genotoxic effects on the human embryo/foetus. Although data on approximately 300 prospectively followed pregnancies with paternal exposure to ribavirin have not shown an increased risk of malformation compared to the general population, nor any specific pattern of malformation, male patients and their female partners of childbearing age must be advised to each use an effective contraceptive during treatment with ribavirin and for seven months after treatment. Men whose partners are pregnant must be instructed to use a condom to minimise delivery of ribavirin to the partner.

Breast-feeding: It is not known whether ribavirin is excreted in human milk. Because of the potential for adverse reactions in breast-fed infants, breast-feeding must be discontinued prior to initiation of treatment.

4.7 Effects on ability to drive and use machines
Ribavirin 200mg Capsules has no or negligible influence on the ability to drive and use machines; however, peginterferon alfa-2b or interferon alfa-2b used in combination may have an effect. Thus, patients who develop fatigue, somnolence, or confusion during treatment must be cautioned to avoid driving or operating machinery.

4.8 Undesirable effects
Adult patients:
The safety of ribavirin capsules is evaluated from data from four clinical trials in patients with no previous exposure to interferon (interferon-naïve patients): two trials studied ribavirin in combination with interferon alfa-2b, two trials studied ribavirin in combination with peginterferon alfa-2b.

Patients who are treated with interferon alfa-2b and ribavirin after previous relapse from interferon therapy or who are treated for a shorter period are likely to have an improved safety profile than that described below.

The adverse reactions listed in Table 4 are based on experience from clinical trials in adult naïve patients treated for 1 year and post-marketing use. A certain number of adverse reactions, generally attributed to interferon therapy but that have been reported in the context of hepatitis C therapy (in combination with ribavirin) are also listed for reference in Table 4. Also, refer to peginterferon alfa-2b and interferon alfa-2b SPCs for adverse reactions that may be attributable to interferons monotherapy. Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1.000 to <1/100); rare (> 1/10.000 to <1/1.000); very rare (<1/10.000); not known. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Adverse Reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>Viral infection, pharyngitis</td>
</tr>
<tr>
<td>Common:</td>
<td>Bacterial infection (including sepsis), fungal infection, influenza, respiratory tract infection, bronchitis, herpes simplex, sinusitis, otitis media, rhinitis, urinary tract infection</td>
</tr>
<tr>
<td>Uncommon</td>
<td>Injection site infection, lower respiratory tract infection</td>
</tr>
<tr>
<td>Rare:</td>
<td>Pneumonia*</td>
</tr>
<tr>
<td>Common: Neoplasms benign, malignant and unspecified (including cysts and polyps)</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Neoplasm unspecified</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood and lymphatic system disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common: Anaemia, neutropenia</td>
</tr>
<tr>
<td>Common: Haemolytic anaemia, leukopenia, thrombocytopenia,</td>
</tr>
<tr>
<td>lymphadenopathy, lymphopenia</td>
</tr>
<tr>
<td>Very rare: Aplastic anaemia*</td>
</tr>
<tr>
<td>Not known: Pure red cell aplasia, idiopathic thrombocytopenic</td>
</tr>
<tr>
<td>purpura, thrombotic thrombocytopenic purpura</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immune system disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon: Drug hypersensitivity</td>
</tr>
<tr>
<td>Rare: Sarcoyidosis*, rheumatoid arthritis (new or aggravated)</td>
</tr>
<tr>
<td>Not known: Vogt-Koyanagi-Harada syndrome, systemic lupus</td>
</tr>
<tr>
<td>erythematosus, vasculitis, acute hypersensitivity reactions</td>
</tr>
<tr>
<td>including urticaria, angioedema, bronchoconstriction,</td>
</tr>
<tr>
<td>anaphylaxis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endocrine disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common: Hypothyroidism, hyperthyroidism</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Metabolism and nutrition disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common: Anorexia</td>
</tr>
<tr>
<td>Common: Hyperglycaemia, hyperuricaemia, hypocalcaemia,</td>
</tr>
<tr>
<td>dehydration, increased appetite</td>
</tr>
<tr>
<td>Uncommon: Diabetes mellitus, hypertriglyceridemia*</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Psychiatric disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common: Depression, anxiety, emotional lability, insomnia</td>
</tr>
<tr>
<td>Common: Suicidal ideation, psychosis, aggressive behaviour,</td>
</tr>
<tr>
<td>confusion, agitation, anger, mood altered, abnormal behaviour,</td>
</tr>
<tr>
<td>nervousness, sleep disorder, decreased libido, apathy, abnormal</td>
</tr>
<tr>
<td>dreams, crying</td>
</tr>
<tr>
<td>Uncommon: Suicide attempts, panic attack, hallucination</td>
</tr>
<tr>
<td>Rare: Bipolar disorder*</td>
</tr>
<tr>
<td>Very rare: Suicide*</td>
</tr>
<tr>
<td>Not known: Homicidal ideation*, mania*, mental status change</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nervous system disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common: Headache, dizziness, dry mouth, concentration impaired</td>
</tr>
<tr>
<td>Common: Amnesia, memory impairment, syncope, migraine, ataxia,</td>
</tr>
<tr>
<td>paraesthesia, dysphonia, taste loss, hypoesthesia,</td>
</tr>
<tr>
<td>hyperaesthesia, hypertonia, somnolence, disturbance in</td>
</tr>
<tr>
<td>attention, tremor, dysgeusia</td>
</tr>
<tr>
<td>Uncommon: Neuropathy, peripheral neuropathy</td>
</tr>
<tr>
<td>Rare: Seizure (convulsion)*</td>
</tr>
<tr>
<td>Very rare: Cerebrovascular haemorrhage*, cerebrovascular</td>
</tr>
<tr>
<td>ischaemia*, encephalopathy*, polyneuropathy*</td>
</tr>
<tr>
<td>Not known: Facial palsy, mononeuropathies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eye disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common: Visual disturbance, blurred vision, conjunctivitis,</td>
</tr>
<tr>
<td>eye irritation, eye pain, abnormal vision, lacrimal gland</td>
</tr>
<tr>
<td>disorder, dry eye</td>
</tr>
<tr>
<td>Rare: Retinal haemorrhages*, retinopathies (including macular</td>
</tr>
<tr>
<td>oedema)<em>, retinal artery occlusion</em>, retinal vein occlusion*,</td>
</tr>
<tr>
<td>optic neuritis*, papilloedema*, loss of visual acuity or visual</td>
</tr>
<tr>
<td>field*, retinal exudates</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ear and labyrinth disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common: Vertigo, hearing impaired/loss, tinnitus, ear pain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cardiac disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common: Palpitation, tachycardia</td>
</tr>
<tr>
<td>Uncommon: Myocardial infarction</td>
</tr>
<tr>
<td>Rare: Cardiomyopathy, arrhythmia*</td>
</tr>
<tr>
<td>Very rare: Cardiac ischaemia*</td>
</tr>
<tr>
<td>Not known: Pericardial effusion*, pericarditis*</td>
</tr>
<tr>
<td>Category</td>
</tr>
<tr>
<td>--------------------------------------------</td>
</tr>
<tr>
<td>Vascular disorders</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
</tr>
<tr>
<td>Gastro-intestinal disorders</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Hepatobiliary disorders</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Renal and urinary disorders</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Reproductive system and breast disorders</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Investigations</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
* Since ribavirin is always prescribed with an alpha interferon product, and the listed adverse drug reactions included reflecting post-marketing experience do not allow precise quantification of frequency, the frequency reported above is from clinical trials using ribavirin in combination with interferon alfa-2b (pegylated or non-pegylated).

A reduction in haemoglobin concentrations by > 4 g/dl was observed in 30 % of patients treated with ribavirin and peginterferon alfa-2b and 37 % of patients treated with ribavirin and interferon alfa-2b. Haemoglobin levels dropped below 10 g/dl in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with either peginterferon alfa-2b or interferon alfa-2b.

Most cases of anaemia, neutropenia, and thrombocytopenia were mild (WHO grades 1 or 2). There were some cases of more severe neutropenia in patients treated with ribavirin in combination with peginterferon alfa-2b (WHO grade 3: 39 of 186 [21 %]; and WHO grade 4: 13 of 186 [7 %]); WHO grade 3 leukopenia was also reported in 7 % of this treatment group.

An increase in uric acid and indirect bilirubin values associated with haemolysis was observed in some patients treated with ribavirin used in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials, but values returned to baseline levels by four weeks after the end of therapy. Among those patients with elevated uric acid levels, very few patients treated with the combination developed clinical gout, none of which required treatment modification or discontinuation from the clinical trials.

HCV/HIV co-infected patients:
For HCV/HIV co-infected patients receiving ribavirin in combination with peginterferon alfa-2b, other adverse reactions (that were not reported in mono-infected patients) which have been reported in the studies with a frequency > 5 % were: oral candidiasis (14 %), lipodystrophy acquired (13 %), CD4 lymphocytes decreased (8 %), appetite decreased (8 %), gamma-glutamyltransferase increased (9 %), back pain (5 %), blood amylase increased (6 %), blood lactic acid increased (5 %), cytolytic hepatitis (6 %), lipase increased (6 %) and pain in limb (6 %).

Mitochondrial toxicity:
Mitochondrial toxicity and lactic acidosis have been reported in HIV-positive patients receiving NRTI regimen and associated-ribavirin for co-HCV infection (see section 4.4).

Laboratory values for HCV/HIV co-infected patients:
Although haematological toxicities of neutropenia, thrombocytopenia and anaemia occurred more frequently in HCV/HIV co-infected patients, the majority could be managed by dose modification and rarely required premature discontinuation of treatment (see section 4.4). Haematological abnormalities were more frequently reported in patients receiving ribavirin in combination with peginterferon alfa-2b when compared to patients receiving ribavirin in combination with interferon alfa-2b. In Study 1 (see section 5.1), decrease in absolute neutrophil count levels below 500 cells/mm³ was observed in 4 % (8/194) of patients and decrease in platelets below 50,000/mm³ was observed in 4 % (8/194) of patients receiving ribavirin in combination with peginterferon alfa-2b. Anaemia (haemoglobin < 9.4 g/dl) was reported in 12 % (23/194) of patients treated with ribavirin in combination with peginterferon alfa-2b.

CD4 lymphocytes decrease:
Treatment with ribavirin in combination with peginterferon alfa-2b was associated with decreases in absolute CD4+ cell counts within the first 4 weeks without a reduction in CD4+ cell percentage. The decrease in CD4+ cell counts was reversible upon dose reduction or cessation of therapy. The use of ribavirin in combination with peginterferon alfa-2b had no observable negative impact on the control of HIV viraemia during therapy or follow-up. Limited safety data (N = 25) are available in co-infected patients with CD4+ cell counts < 200/microlitre (see section 4.4).

Please refer to the respective Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin in combination with peginterferon alfa-2b.

Children and adolescents:
In combination with peginterferon alfa-2b
In a clinical trial with 107 children and adolescent patients (3 to 17 years of age) treated with combination therapy of peginterferon alfa-2b and ribavirin, dose modifications were required in 25 % of patients, most commonly for anaemia, neutropenia and weight loss. In general, the adverse reactions
profile in children and adolescents was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition. During combination therapy for up to 48 weeks with pegylated interferon alfa-2b and ribavirin, growth inhibition is observed, the reversibility of which is uncertain (see section 4.4). Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3rd percentile in 70 % of the patients).

At the end of 24 weeks post-treatment follow-up, mean decrease from baseline in weight and height percentiles were still 3 percentiles and 7 percentiles, respectively, and 20 % of the children continued to have inhibited growth (growth velocity < 3rd percentile). Based on interim data from the long-term follow-up portion of this study, 22 % (16/74) of children had a > 15 percentile decrease in height percentile, of whom 3 (4 %) children had a > 30 percentile decrease despite being off treatment for more than 1 year. In particular, decrease in mean height percentile at year 1 of long term follow-up was most prominent in prepubertal age children (see section 4.4).

In this study, the most prevalent adverse reactions in all subjects were pyrexia (80 %), headache (62 %), neutropenia (33 %), fatigue (30 %), anorexia (29 %) and injection-site erythema (29 %). Only 1 subject discontinued therapy as the result of an adverse reaction (thrombocytopenia). The majority of adverse reactions reported in the study were mild or moderate in severity. Severe adverse reactions were reported in 7 % (8/107) of all subjects and included injection site pain (1 %), pain in extremity (1 %), headache (1 %), neutropenia (1 %), and pyrexia (4 %). Important treatment-emergent adverse reactions that occurred in this patient population were nervousness (8 %), aggression (3 %), anger (2 %), depression/depressed mood (4 %) and hypothyroidism (3 %) and 5 subjects received levothyroxine treatment for hypothyroidism/elevated TSH.

In combination with interferon alfa-2b

In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and ribavirin, 6 % discontinued therapy due to adverse reactions. In general, the adverse reaction profile in the limited children and adolescent population studied was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition, as decrease in height percentile (mean percentile decrease of 9 percentile) and weight percentile (mean percentile decrease of 13 percentile) were observed during treatment. Within the 5 years follow-up post-treatment period, the children had a mean height of 44th percentile, which was below the median of the normative population and less than their mean baseline height (48th percentile). Twenty (21 %) of 97 children had a > 15 percentile decrease in height percentile, of whom 10 of the 20 children had a > 30 percentile decrease in their height percentile from the start of treatment to the end of long-term follow-up (up to 5 years). During combination therapy for up to 48 weeks with interferon alfa-2b and ribavirin, growth inhibition is observed, the reversibility of which is uncertain. In particular, decrease in mean height percentile from baseline to the end of the long-term follow-up was most prominent in prepubertal age children (see section 4.4).

Furthermore, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % vs. 1 %) during treatment and during the 6 month follow-up after treatment. As in adult patients, children and adolescents also experienced other psychiatric adverse reactions (e.g., depression, emotional lability, and somnolence) (see section 4.4). In addition, injection site disorders, pyrexia, anorexia, vomiting and emotional lability occurred more frequently in children and adolescents compared to adult patients. Dose modifications were required in 30 % of patients, most commonly for anaemia and neutropenia.

Reported adverse reactions listed in Table 5 are based on experience from the two multicentre children and adolescents clinical trials using ribavirin with interferon alfa-2b or peginterferon alfa-2b. Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10), and uncommon (≥ 1/1,000 to < 1/100). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

<table>
<thead>
<tr>
<th>Table 5</th>
<th>Adverse reactions very commonly, commonly and uncommonly reported during clinical trials in children and adolescents with ribavirin in combination with interferon alfa-2b or peginterferon alfa-2b</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>System Organ Class</strong></td>
<td><strong>Adverse Reactions</strong></td>
</tr>
<tr>
<td>Infections and infestations</td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Viral infection, pharyngitis</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Fungal infection, bacterial infection, pulmonary infection, nasopharyngitis, pharyngitis streptococcal, otitis media, sinusitis, tooth abscess, influenza, oral herpes, herpes simplex, urinary tract infection, vaginitis, gastroenteritis</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Pneumonia, ascariasis, enterobiasis, herpes zoster, cellulitis</td>
</tr>
<tr>
<td><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Neoplasm unspecified</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Anaemia, neutropenia</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Thrombocytopenia, lymphadenopathy</td>
</tr>
<tr>
<td><strong>Endocrine disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Hypothyroidism</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Hyperthyroidism, virilism</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Anorexia, increased appetite, decreased appetite</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Hypertriglyceridemia, hyperuricemia</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Depression, insomnia, emotional lability</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Suicidal ideation, aggression, confusion, affect liability, behaviour disorder, agitation, somnambulism, anxiety, mood altered, restlessness, nervousness, sleep disorder, abnormal dreaming, apathy</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Abnormal behaviour, depressed mood, emotional disorder, fear, nightmare</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Headache, dizziness</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Hyperkinesia, tremor, dysphonia, paresthesia, hypoesthesia, hyperaesthesia, concentration impaired, somnolence, disturbance in attention, poor quality of sleep</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Neuralgia, lethargy, psychomotor hyperactivity</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Conjunctivitis, eye pain, abnormal vision, lacrimal gland disorder</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Conjunctival haemorrhage, eye pruritus, keratitis, vision blurred, photophobia</td>
</tr>
<tr>
<td><strong>Ear and labyrinth disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Vertigo</td>
</tr>
<tr>
<td><strong>Cardiac disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Tachycardia, palpitations</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Pallor, flushing</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Hypotension</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Dyspnoea, tachypnea, epistaxis, coughing, nasal congestion, nasal irritation, rhinorrhea, sneezing, pharyngolaryngeal pain</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Wheezing, nasal discomfort</td>
</tr>
<tr>
<td><strong>Gastro-intestinal disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Very common:</strong></td>
<td>Abdominal pain, abdominal pain upper, vomiting, diarrhoea, nausea</td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Mouth ulceration, stomatitis ulcerative, stomatitis, aphthous stomatitis, dyspepsia, cheilosis, glossitis, gastroesophageal reflux, rectal disorder, gastrointestinal disorder, constipation, loose stools, toothache, tooth disorder, stomach discomfort, oral pain</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Gingivitis</td>
</tr>
<tr>
<td><strong>Hepatobiliary disorders</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common:</strong></td>
<td>Hepatic function abnormal</td>
</tr>
<tr>
<td><strong>Uncommon:</strong></td>
<td>Hepatomegaly</td>
</tr>
<tr>
<td><strong>Skin and subcutaneous tissue disorders</strong></td>
<td></td>
</tr>
</tbody>
</table>
PAR Ribavirin 200mg Capsules

| Very common: | Alopecia, rash |
| Common: | Pruritus, photosensitivity reaction, maculopapular rash, eczema, hyperhidrosis, acne, skin disorder, nail disorder, skin discolouration, dry skin, erythema, bruise |
| Uncommon: | Pigmentation disorder, dermatitis atopic, skin exfoliation |

**Musculoskeletal and connective tissue disorders**

| Very common: | Arthralgia, myalgia, musculoskeletal pain |
| Common: | Pain in extremity, back pain, muscle contracture |

**Renal and urinary disorders**

| Common: | Enuresis, micturition disorder, urinary incontinence, proteinuria |

**Reproductive system and breast disorders**

| Common: | Female: amenorrhea, menorrhagia, menstrual disorder, vaginal disorder, Male: testicular pain |
| Uncommon: | Female: dysmenorrhoea |

**General disorders and administration site conditions**

| Very common: | Injection site inflammation, injection site reaction, injection site erythema, injection site pain, fatigue, rigors, pyrexia, influenza-like illness, asthenia, malaise, irritability |
| Common: | Chest pain, oedema, pain, injection site pruritus, injection site rash, injection site dryness, feeling cold |
| Uncommon: | Chest discomfort, facial pain, injection site induration |

**Investigations**

| Very common: | Growth rate decrease (height and/or weight decrease for age) |
| Common: | Blood thyroid stimulating hormone increased, thyroglobulin increased |
| Uncommon: | Anti-thyroid antibody positive |

**Injury, poisoning and procedural complications**

| Common: | Skin laceration |
| Uncommon: | Contusion |

Most of the changes in laboratory values in the ribavirin/peginterferon alfa-2b clinical trial were mild or moderate. Decreases in haemoglobin, white blood cells, platelets, neutrophils and increase in bilirubin may require dose reduction or permanent discontinuation from therapy (see section 4.2). While changes in laboratory values were observed in some patients treated with ribavirin used in combination with peginterferon alfa-2b in the clinical trial, values returned to baseline levels within a few weeks after the end of therapy.

4.9 **Overdose**

In clinical trials with ribavirin used in combination with peginterferon alfa-2b or interferon alfa-2b, the maximum overdose reported was a total dose of 10 g of ribavirin (50 x 200 mg capsules) and 39 MIU of interferon alfa-2b (13 subcutaneous injections of 3 MIU each) taken in one day by a patient in an attempt at suicide. The patient was observed for two days in the emergency room, during which time no adverse reaction from the overdose was noted.

5 **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**

Pharmacotherapeutic group: Direct acting antivirals, nucleosides and nucleotides (excl. reverse transcriptase inhibitors), ATC code: J05A B04.

Ribavirin (Ribavirin 200mg Capsules) is a synthetic nucleoside analogue which has shown in vitro activity against some RNA and DNA viruses. The mechanism by which ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b exerts its effects against HCV is unknown. Oral formulations of ribavirin monotherapy have been investigated as therapy for chronic hepatitis C in several clinical trials. Results of these investigations showed that ribavirin monotherapy had no effect on eliminating hepatitis virus (HCV-RNA) or improving hepatic histology after 6 to 12 months of therapy and 6 months of follow-up.

Ribavirin clinical trials in adults

The use of ribavirin in combination treatment with peginterferon alfa-2b or interferon alfa-2b was evaluated in a number of clinical trials. Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 30 IU/ml), a liver
biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.

**Naïve patients**

Three trials examined the use of interferon in naïve patients, two with ribavirin + interferon alfa-2b (C95-132 and I95-143) and one with ribavirin + peginterferon alfa-2b (C/I98-580). In all cases the treatment was for one year with a follow-up of six months. The sustained response at the end of follow-up was significantly increased by the addition of ribavirin to interferon alfa-2b (41 % vs 16 %, p < 0.001).

In clinical trials C95-132 and I95-143, ribavirin + interferon alfa-2b combination therapy proved to be significantly more effective than interferon alfa-2b monotherapy (a doubling in sustained response). Combination therapy also decreased the relapse rate. This was true for all HCV genotypes, particularly Genotype 1, in which the relapse rate was reduced by 30 % compared with interferon alfa-2b monotherapy.

In clinical trial C/I98-580, 1,530 naïve patients were treated for one year with one of the following combination regimens:

- ribavirin (800 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week) (n = 511).
- ribavirin (1,000/1,200 mg/day) + peginterferon alfa-2b (1.5 micrograms/kg/week for one month followed by 0.5 microgram/kg/week for 11 months) (n = 514).
- ribavirin (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505).

In this trial, the combination of ribavirin and peginterferon alfa-2b (1.5 micrograms/kg/week) was significantly more effective than the combination of ribavirin and interferon alfa-2b, particularly in patients infected with Genotype 1. Sustained response was assessed by the response rate six months after the cessation of treatment.

HCV genotype and baseline virus load are prognostic factors which are known to affect response rates. However, response rates in this trial were shown to be dependent also on the dose of ribavirin administered in combination with peginterferon alfa-2b or interferon alfa-2b. In those patients that received > 10,6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10,6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13,2 mg/kg ribavirin were even higher.

<table>
<thead>
<tr>
<th>HCV Genotype</th>
<th>ribavirin dose (mg/kg)</th>
<th>P 1.5/R</th>
<th>P 0.5/R</th>
<th>I/R</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Genotypes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>≤10,6</td>
<td>54 %</td>
<td>47 %</td>
<td>47 %</td>
</tr>
<tr>
<td></td>
<td>&gt; 10,6</td>
<td>50 %</td>
<td>41 %</td>
<td>27 %</td>
</tr>
<tr>
<td>Genotype 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>≤10,6</td>
<td>42 %</td>
<td>34 %</td>
<td>33 %</td>
</tr>
<tr>
<td></td>
<td>&gt; 10,6</td>
<td>48 %</td>
<td>34 %</td>
<td>34 %</td>
</tr>
<tr>
<td>Genotype 1</td>
<td>≤600,000 IU/ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>≤10,6</td>
<td>73 %</td>
<td>51 %</td>
<td>45 %</td>
</tr>
<tr>
<td></td>
<td>&gt; 10,6</td>
<td>74 %</td>
<td>25 %</td>
<td>33 %</td>
</tr>
<tr>
<td>Genotype 1</td>
<td>&gt; 600,000 IU/ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>≤10,6</td>
<td>30 %</td>
<td>27 %</td>
<td>29 %</td>
</tr>
<tr>
<td></td>
<td>&gt; 10,6</td>
<td>27 %</td>
<td>25 %</td>
<td>17 %</td>
</tr>
<tr>
<td>Genotype 2/3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>≤10,6</td>
<td>82 %</td>
<td>80 %</td>
<td>79 %</td>
</tr>
<tr>
<td></td>
<td>&gt; 10,6</td>
<td>80 %</td>
<td>80 %</td>
<td>80 %</td>
</tr>
</tbody>
</table>

P1.5/R ribavirin (800 mg) + peginterferon alfa-2b (1,5 micrograms/kg)
P0.5/R ribavirin (1,000/1,200 mg) + peginterferon alfa-2b (1,5 to 0,5 microgram/kg)
I/R ribavirin (1,000/1,200 mg) + interferon alfa-2b (3 MIU)

In a separate trial, 224 patients with genotype 2 or 3 received peginterferon alfa-2b, 1,5 microgram/kg subcutaneously, once weekly, in combination with ribavirin 800 mg - 1.400 mg p.o. for 6 months (based on body weight, only three patients weighing > 105 kg, received the 1.400 mg dose) (Table 7). Twenty-four % had bridging fibrosis or cirrhosis (Knodell 3/4).
Table 7  Virologic Response at End of Treatment, Sustained Virologic Response and  Relapse by
HCV Genotype and Viral Load*

<table>
<thead>
<tr>
<th></th>
<th>Ribavirin 800-1,400 mg/day plus peginterferon alfa-2b 1.5 μg/kg once weekly</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>End of Treatment Response</td>
</tr>
<tr>
<td>All Subjects</td>
<td>94 % (211/224)</td>
</tr>
<tr>
<td>HCV 2 ≤ 600,000 IU/ml</td>
<td>100 % (42/42)</td>
</tr>
<tr>
<td></td>
<td>100 % (20/20)</td>
</tr>
<tr>
<td></td>
<td>100 % (22/22)</td>
</tr>
<tr>
<td>HCV 2 &gt; 600,000 IU/ml</td>
<td>93 % (169/182)</td>
</tr>
<tr>
<td></td>
<td>93 % (92/99)</td>
</tr>
<tr>
<td></td>
<td>93 % (77/83)</td>
</tr>
<tr>
<td>HCV 3 ≤ 600,000 IU/ml</td>
<td>93 % (169/182)</td>
</tr>
<tr>
<td></td>
<td>93 % (92/99)</td>
</tr>
<tr>
<td></td>
<td>93 % (77/83)</td>
</tr>
</tbody>
</table>

* Any subject with an undetectable HCV-RNA level at the follow-up week 12 visit and missing data at
the follow-up week 24 visit was considered a sustained responder. Any subject with missing data in
and after the follow-up week 12 window was considered to be a non-responder at week 24 of follow-
up.

The 6 month treatment duration in this trial was better tolerated than one year of treatment in the
pivotal combination trial; for discontinuation 5 % vs. 14 %, for dose modification 18 % vs. 49 %.

In a non-comparative trial, 235 patients with genotype 1 and low viral load (< 600,000 IU/ml) received
peginterferon alfa-2b, 1,5 microgram/kg subcutaneously, once weekly, in combination with weight
adjusted ribavirin. The overall sustained response rate after a 24-week treatment duration was 50 %.
Forty-one percent of subjects (97/235) had nondetectable plasma HCV-RNA levels at week 4 and week
24 of therapy. In this subgroup, there was a 92 % (89/97) sustained virological response rate. The high
sustained response rate in this subgroup of patients was identified in an interim analysis (n=49) and
prospectively confirmed (n=48).
Limited historical data indicate that treatment for 48 weeks might be associated with a higher sustained
response rate (11/11) and with a lower risk of relapse (0/11 as compared to 7/96 following 24 weeks of
treatment).

A large randomized trial compared the safety and efficacy of treatment for 48 weeks with two
peginterferon alfa-2b/ribavirin regimens [peginterferon alfa-2b 1,5 microgram/kg and 1 microgram/kg
subcutaneously once weekly both in combination with ribavirin 800 to 1,400 mg p.o. daily (in two
divided doses)] and peginterferon alfa-2a 180 microgram subcutaneously once weekly with ribavirin
1,000 to 1,200 mg p.o. daily (in two divided doses) in 3,070 treatment-naïve adults with chronic
hepatitis C genotype 1. Response to the treatment was measured by Sustained Virologic Response
(SVR) which is defined as undetectable HCV-RNA at 24 weeks post-treatment (see Table 8).

Table 8  Virologic response at treatment week 12, end of treatment response, relapse
rate* and Sustained Virologic Response (SVR)

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>% (number) of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>peginterferon alfa-2b 1.5 μg/kg + ribavirin</td>
</tr>
<tr>
<td>Undetectable HCV-RNA at treatment week 12</td>
<td>40 (407/1.019)</td>
</tr>
<tr>
<td>End of treatment response*</td>
<td>53 (542/1.019)</td>
</tr>
<tr>
<td>Relapse*</td>
<td>24 (123/523)</td>
</tr>
<tr>
<td>SVR*</td>
<td>40 (406/1.019)</td>
</tr>
<tr>
<td>SVR in patients with undetectable HCV-RNA at treatment week 12</td>
<td>81 (328/407)</td>
</tr>
</tbody>
</table>

*HCV-RNA PCR assay, with a lower limit of quantitation of 27 IU/ml
Lack of early virologic response by treatment week 12 (detectable HCV-RNA with a < 2 log10
reduction from baseline) was a criterion for discontinuation of treatment.
In all three treatment groups, sustained virologic response rates were similar. In patients of African American origin (which is known to be a poor prognostic factor for HCV eradication), treatment with peginterferon alfa-2b (1.5 microgram/kg)/ribavirin combination therapy resulted in a higher sustained virologic response rate compared to peginterferon alfa-2b 1 microgram/kg dose. At the peginterferon alfa-2b 1.5 microgram/kg plus ribavirin dose, sustained virologic response rates were lower in patients with cirrhosis, in patients with normal ALT levels, in patients with a baseline viral load > 600,000 IU/ml and in patients > 40 years old. Caucasian patients had a higher sustained virologic response rate compared to the African Americans. Among patients with undetectable HCV-RNA at the end of treatment, the relapse rate was 24 %.

*Predictability of sustained virological response in naïve patients*
Virological response by week 12 is defined as at least 2-log viral load decrease or undetectable levels of HCV-RNA. Virological response by week 4 is defined as at least 1-log viral load decrease or undetectable levels of HCV-RNA. These time points (treatment week 4 and treatment week 12) have been shown to be predictive for sustained response (Table 9).

<table>
<thead>
<tr>
<th>Table 9</th>
<th>Predictive Value of In-Treatment Virologic Response while on peginterferon alfa-2b 1.5 μg/kg/ribavirin 800-1,400 mg Combination Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genotype 1</strong></td>
<td><strong>Negative</strong></td>
</tr>
<tr>
<td><strong>By Week 4</strong>* (n= 950)</td>
<td></td>
</tr>
<tr>
<td>HCV-RNA negative</td>
<td>834</td>
</tr>
<tr>
<td>HCV-RNA negative or ≥ 1 log decrease in viral load</td>
<td>220</td>
</tr>
<tr>
<td><strong>By Week 12</strong>* (n= 915)</td>
<td></td>
</tr>
<tr>
<td>HCV-RNA negative</td>
<td>508</td>
</tr>
<tr>
<td>HCV-RNA negative or ≥ 2 log decrease in viral load</td>
<td>206</td>
</tr>
<tr>
<td><strong>Genotype 2, 3</strong></td>
<td><strong>By Week 12</strong> (n=215)</td>
</tr>
<tr>
<td>HCV-RNA negative or ≥ 2 log</td>
<td>2</td>
</tr>
</tbody>
</table>

† N/A: Not Applicable
decrease in viral load

*Genotype 1 receive 48 weeks treatment
**Genotype 2, 3 receive 24 weeks treatment
***The presented results are from a single point of time. A patient may be missing or have had a different result for week 4 or week 12.
† These criteria were used in the protocol: If week 12 HCV-RNA is positive and $< 2 \log_{10}$ decrease from baseline, patients to stop therapy. If week 12 HCV-RNA is positive and decreased $\geq 2 \log_{10}$ from baseline, then retest HCV-RNA at week 24 and if positive, patients to stop therapy.

**HCV/HIV Co-infected patients**

Two trials have been conducted in patients co-infected with HIV and HCV. The response to treatment in both of these trials is presented in Table 10. Study 1 (RIBAVIC; P01017) was a randomized, multicentre study which enrolled 412 previously untreated adult patients with chronic hepatitis C who were co-infected with HIV. Patients were randomized to receive either ribavirin (800 mg/day) plus peginterferon alfa-2b (1.5 microgram/kg/week) or ribavirin (800 mg/day) plus interferon alfa-2b (3 MIU TIW) for 48 weeks with a follow-up period of 6 months. Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co-infected with HIV. Patients were randomized to receive either ribavirin (800 - 1.200 mg/day based on weight) plus peginterferon alfa-2b (100 or 150 microgram/week based on weight) or ribavirin (800 - 1.200 mg/day based on weight) plus interferon alfa-2b (3 MIU TIW). The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800.000 IU/ml (Amplicor) who were treated for 24 weeks with a 6 month follow-up period.

**Table 10**  Sustained virological response based on genotype after ribavirin in combination with peginterferon alfa-2b in HCV/HIV co-infected patients

<table>
<thead>
<tr>
<th>Study 1</th>
<th>Study 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ribavirin (800 mg/day) + peginterferon alfa-2b (1.5 μg/kg/week)</td>
<td>Ribavirin (800 mg/day) + interferon alfa-2b (3 MIU TIW)</td>
</tr>
<tr>
<td>Ribavirin (800 g/day) + interferon alfa-2b (3 MIU TIW)</td>
<td>Ribavirin (800-1,200 mg/day)$^d$ + peginterferon alfa-2b (100 or 150 μg/week)</td>
</tr>
<tr>
<td>p value$^a$</td>
<td>p value$^b$</td>
</tr>
<tr>
<td>All</td>
<td>27 % (56/205)</td>
</tr>
<tr>
<td>20 % (41/205)</td>
<td>0.047</td>
</tr>
<tr>
<td>Genotype 1, 4</td>
<td>17 % (21/125)</td>
</tr>
<tr>
<td>6 % (8/129)</td>
<td>0.006</td>
</tr>
<tr>
<td>Genotype 2, 3</td>
<td>44 % (35/80)</td>
</tr>
<tr>
<td>43 % (33/76)</td>
<td>0.88</td>
</tr>
</tbody>
</table>

MIU = million international units; TIW = three times a week.
$^a$: p value based on Cochran-Mantel Haenszel Chi square test.
$^b$: p value based on chi-square test.
$^c$: subjects < 75 kg received 100 μg/week peginterferon alfa-2b and subjects ≥ 75 kg received 150 μg/week peginterferon alfa-2b.
$^d$: ribavirin dosing was 800 mg for patients < 60 kg, 1,000 mg for patients 60 - 75 kg, and 1,200 mg for patients > 75 kg.


**Histological response**

Liver biopsies were obtained before and after treatment in Study 1 and were available for 210 of the 412 subjects (51 %). Both the Metavir score and Ishak grade decreased among subjects treated with ribavirin in combination with peginterferon alfa-2b. This decline was significant among responders (-0.3 for Metavir and -1.2 for Ishak) and stable (-0.1 for Metavir and -0.2 for Ishak) among non-responders. In terms of activity, about one-third of sustained responders showed improvement and none
showed worsening. There was no improvement in terms of fibrosis observed in this study. Steatosis was significantly improved in patients infected with HCV Genotype 3.

**Previously treated patients**
- Retreatment of prior treatment failures (relapse and non-responder patients) with peginterferon alfa-2b in combination with ribavirin.
- In a non-comparative trial, 2,293 patients with moderate to severe fibrosis who failed previous treatment with combination alpha interferon/ribavirin were retreated with peginterferon alfa-2b, 1.5 microgram/kg subcutaneously, once weekly, in combination with weight adjusted ribavirin. Failure to prior therapy was defined as relapse or non-response (HCV-RNA positive at the end of a minimum of 12 weeks of treatment).

Patients who were HCV-RNA negative at Treatment week 12 continued treatment for 48 weeks and were followed for 24 weeks post-treatment. Response week 12 was defined as undetectable HCV-RNA after 12 weeks of treatment. Sustained Virologic Response (SVR) is defined as undetectable HCV-RNA at 24 weeks post-treatment (Table 11).

### Table 11 Rates of Response to retreatment in prior treatment failures

<table>
<thead>
<tr>
<th>Patients with undetectable HCV–RNA at treatment week 12 and SVR upon retreatment</th>
<th>peginterferon alpha/ribavirin</th>
<th>Overall Population*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Response week 12 % (n/N)</strong></td>
<td><strong>SVR % (n/N) 99% CI</strong></td>
<td><strong>SVR % (n/N) 99% CI</strong></td>
</tr>
<tr>
<td>Overall</td>
<td>38.6 (549/1,423)</td>
<td>59.4 (326/549) 54.0; 64.8</td>
</tr>
<tr>
<td>Prior Response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapse</td>
<td>67.7 (203/300)</td>
<td>59.6 (121/203) 50.7; 68.5</td>
</tr>
<tr>
<td>Genotype 1/4</td>
<td>59.7 (129/216)</td>
<td>51.2 (66/129) 39.8; 62.5</td>
</tr>
<tr>
<td>Genotype 2/3</td>
<td>88.9 (72/81)</td>
<td>73.6 (53/72) (60.2; 87.0)</td>
</tr>
<tr>
<td>NR</td>
<td>28.6 (258/903)</td>
<td>57.0 (147/258) 49.0; 64.9</td>
</tr>
<tr>
<td>Genotype 1/4</td>
<td>23.0 (182/790)</td>
<td>51.6 (94/182) 42.1; 61.2</td>
</tr>
<tr>
<td>Genotype 2/3</td>
<td>67.9 (74/109)</td>
<td>70.3 (52/74) 56.6; 84.0</td>
</tr>
<tr>
<td>Genotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>30.2 (343/1,135)</td>
<td>51.3 (176/343) 44.4; 58.3</td>
</tr>
<tr>
<td>2/3</td>
<td>77.1 (185/240)</td>
<td>73.0 (135/185) 64.6; 81.4</td>
</tr>
<tr>
<td>4</td>
<td>42.5 (17/40)</td>
<td>70.6 (12/17) 42.1; 99.1</td>
</tr>
<tr>
<td>METAVIR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrosis score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>F2</td>
<td>46.0 (193/420)</td>
<td>66.8 (129/193) 58.1; 75.6</td>
</tr>
<tr>
<td>F3</td>
<td>38.0 (163/429)</td>
<td>62.6 (102/163) 32.4</td>
</tr>
<tr>
<td>Baseline Viral Load</td>
<td>F4</td>
<td>HVL (&gt;600,000 IU/ml)</td>
</tr>
<tr>
<td>---------------------</td>
<td>-----</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| NR: Non-responder defined as serum/plasma HCV-RNA positive at the end of a minimum of 12 weeks of treatment. Plasma HCV-RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory. *Intent to treat population includes 7 patients for whom at least 12 weeks of prior therapy could not be confirmed. Overall, approximately 36 % (821/2,286) of patients had undetectable plasma HCV-RNA levels at week 12 of therapy measured using a research-based test (limit of detection 125 IU/ml). In this subgroup, there was a 56 % (463/823) sustained virological response rate. For patients with prior failure on therapy with non-pegylated interferon or pegylated interferon and negative at week 12, the sustained response rates were 59 % and 50 %, respectively. Among 480 patients with > 2 log viral reduction but detectable virus at week 12, altogether 188 patients continued therapy. In those patients the SVR was 12 %. Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to non-pegylated interferon alpha/ribavirin (12.4 % vs. 28.6 %). However, if a week 12 response was achieved, there was little difference in SVR regardless of prior treatment or prior response. - Retreatment of relapse patients with ribavirin and interferon alfa-2b combination treatment Two trials examined the use of ribavirin and interferon alfa-2b combination treatment in relapse patients (C95-144 and I95-145); 345 chronic hepatitis patients who had relapsed after previous interferon treatment were treated for six months with a six month follow-up. Combination therapy with ribavirin and interferon alfa-2b resulted in a sustained virological response that was ten-fold higher than that with interferon alfa-2b alone (49 % vs 5 %, p < 0.0001). This benefit was maintained irrespective of standard predictors of response to interferon alfa-2b such as virus level, HCV genotype and histological staging. Long-term efficacy data - Adults Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with non-pegylated interferon alfa-2b (with or without ribavirin) and pegylated interferon alfa-2b (with or without ribavirin), respectively. The purpose of the studies was to evaluate the durability of sustained virologic response (SVR) and assess the impact of continued viral negativity on clinical outcomes. At least 5 years of long-term follow-up was completed after treatment in 462 patients and 327 patients, respectively. Twelve out of 492 sustained responders and only 3 out of 366 sustained responders relapsed, respectively, in the studies. The Kaplan-Meier estimate for continued sustained response over 5 years is 97 % (95 % CI: 95 - 99 %) for patients receiving non-pegylated interferon alfa-2b (with or without ribavirin), and is 99 % (95 % CI: 98-100 %) for patients receiving pegylated interferon alfa-2b (with or without ribavirin). SVR after treatment of chronic HCV with interferon alfa-2b (pegylated and non-pegylated, with or without ribavirin) results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV. However, this does not preclude the occurrence of hepatic events in patients with cirrhosis (including hepatocarcinoma). Ribavirin clinical trials in children and adolescents: Ribavirin in combination with peginterferon alfa-2b Children and adolescents 3 to 17 years of age with compensated chronic hepatitis C and detectable HCV-RNA were enrolled in a multicentre trial and treated with ribavirin 15 mg/kg per day plus pegylated interferon alfa-2b 60 microgram/m² once weekly for 24 or 48 weeks, based on HCV
genotype and baseline viral load. All patients were to be followed for 24 weeks post-treatment. A total of 107 patients received treatment of whom 52 % were female, 89 % Caucasian, 67 % with HCV Genotype 1 and 63 % < 12 years of age. The population enrolled mainly consisted of children with mild to moderate hepatitis C. Due to the lack of data in children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of ribavirin and pegylated interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8).

The study results are summarized in Table 12.

<table>
<thead>
<tr>
<th>Genotype and Treatment Duration</th>
<th>All Subjects</th>
<th>24 weeks</th>
<th>48 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Genotypes</td>
<td>26/27 (96 %)</td>
<td>44/80 (55 %)</td>
<td></td>
</tr>
<tr>
<td>Genotype 1</td>
<td></td>
<td>38/72 (53 %)</td>
<td></td>
</tr>
<tr>
<td>Genotype 2</td>
<td>14/15 (93 %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype 3&lt;sup&gt;c&lt;/sup&gt;</td>
<td>12/12 (100 %)</td>
<td>2/3 (67 %)</td>
<td></td>
</tr>
<tr>
<td>Genotype 4</td>
<td></td>
<td>4/5 (80 %)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>: Response to treatment was defined as undetectable HCV-RNA at 24 weeks post-treatment, lower limit of detection = 125 IU/ml.

<sup>b</sup>: n = number of responders/number of subjects with given genotype, and assigned treatment duration.

<sup>c</sup>: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (> 600,000 IU/ml) were to receive 48 weeks of treatment.

**Ribavirin in combination with interferon alfa-2b**

Children and adolescents 3 to 16 years of age with compensated chronic hepatitis C and detectable HCV-RNA (assessed by a central laboratory using a research-based RT-PCR assay) were enrolled in two multicentre trials and received ribavirin 15 mg/kg per day plus interferon alfa-2b 3 MIU/m² 3 times a week for 1 year followed by 6 months follow-up after treatment. A total of 118 patients were enrolled: 57 % male, 80 % Caucasian, and 78 % genotype 1, 64 % ≤ 12 years of age. The population enrolled mainly consisted in children with mild to moderate hepatitis C. In the two multicentre trials, sustained virological response rates in children and adolescents were similar to those in adults. Due to the lack of data in these two multicentre trials for children with severe progression of the disease, and the potential for undesirable effects, the benefit/risk of the combination of ribavirin and interferon alfa-2b needs to be carefully considered in this population (see sections 4.1, 4.4 and 4.8). The study results are summarized in Table 13.

<table>
<thead>
<tr>
<th>Ribavirin 15 mg/kg/day</th>
<th>Overall Response&lt;sup&gt;a&lt;/sup&gt; (n = 118) + interferon alfa-2b 3 MIU/m² 3 times a week</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>54 (46 %)*</td>
</tr>
<tr>
<td>Genotype 1 (n = 92)</td>
<td>33 (36 %)*</td>
</tr>
<tr>
<td>Genotype 2/3/4 (n = 26)</td>
<td>21 (81 %)*</td>
</tr>
</tbody>
</table>

<sup>*</sup> Number (%) of patients

<sup>a</sup>: Defined as HCV-RNA below limit of detection using a research based RT-PCR assay at end of treatment and during follow-up period.

**Long-term efficacy data - Children and adolescents**

A five-year long-term, observational, follow-up study enrolled 97 paediatric chronic hepatitis C patients after treatment in two previously mentioned multicentre trials. Seventy percent (68/97) of all enrolled subjects completed this study of which 75 % (42/56) were sustained responders. The purpose of the study was to annually evaluate the durability of sustained virologic response (SVR) and assess the impact of continued viral negativity on clinical outcomes for patients who were sustained responders 24 weeks post-treatment of the 48-week interferon alfa-2b and ribavirin treatment. All but one of the paediatric subjects remained sustained virologic responders during long-term follow-up after completion of treatment with interferon alfa-2b plus ribavirin. The Kaplan-Meier estimate for continued sustained response over 5 years is 98 % [95 % CI: 95 %, 100 %] for paediatric patients treated with interferon alfa-2b and ribavirin. Additionally, 98 % (51/52) with normal ALT levels at follow-up week 24 maintained normal ALT levels at their last visit.
SVR after treatment of chronic HCV with non-pegylated interferon alfa-2b with ribavirin results in long-term clearance of the virus providing resolution of the hepatic infection and clinical 'cure' from chronic HCV. However, this does not preclude the occurrence of hepatic events in patients with cirrhosis (including hepatocarcinoma).

5.2 Pharmacokinetic properties

Ribavirin is absorbed rapidly following oral administration of a single dose (mean $T_{max}=1.5$ hours), followed by rapid distribution and prolonged elimination phases (single dose half-lives of absorption, distribution and elimination are 0.05, 3.73 and 79 hours, respectively). Absorption is extensive with approximately 10% of a radiolabelled dose excreted in the faeces. However, absolute bioavailability is approximately 45% - 65%, which appears to be due to first pass metabolism. There is a linear relationship between dose and $AUC_{d}$ following single doses of 200 - 1,200 mg ribavirin. Volume of distribution is approximately 5,000 l. Ribavirin does not bind to plasma proteins.

Ribavirin has been shown to produce high inter- and intra-subject pharmacokinetic variability following single oral doses (intrasubject variability of approximately 30% for both $AUC$ and $C_{max}$), which may be due to extensive first pass metabolism and transfer within and beyond the blood compartment.

Ribavirin transport in non-plasma compartments has been most extensively studied in red cells, and has been identified to be primarily via an $e_{r}$-type equilibrative nucleoside transporter. This type of transporter is present on virtually all cell types and may account for the high volume of distribution of ribavirin. The ratio of whole blood: plasma ribavirin concentrations is approximately 60:1; the excess of ribavirin in whole blood exists as ribavirin nucleotides sequestered in erythrocytes.

Ribavirin has two pathways of metabolism: 1) a reversible phosphorylation pathway; 2) a degradative pathway involving deribosylation and amide hydrolysis to yield a triazole carboxyacid metabolite. Both ribavirin and its triazole carbamoyl and triazole carboxylic acid metabolites are also excreted renally.

Upon multiple dosing, ribavirin accumulates extensively in plasma with a six-fold ratio of multiple-dose to single-dose $AUC_{12hr}$. Following oral dosing with 600 mg BID, steady-state was reached by approximately four weeks, with mean steady state plasma concentrations approximately 2,200 ng/ml. Upon discontinuation of dosing the half-life was approximately 298 hours, which probably reflects slow elimination from non-plasma compartments.

Food effect: The bioavailability of a single oral dose of ribavirin was increased by co-administration of a high fat meal ($AUC_{tf}$ and $C_{max}$ both increased by 70%). It is possible that the increased bioavailability in this study was due to delayed transit of ribavirin or modified pH. The clinical relevance of results from this single dose study is unknown. In the pivotal clinical efficacy trial, patients were instructed to take ribavirin with food to achieve the maximal plasma concentration of ribavirin.

Renal function: Single-dose ribavirin pharmacokinetics were altered (increased $AUC_{d}$ and $C_{max}$) in patients with renal dysfunction compared with control subjects (creatinine clearance > 90 ml/minute). This appears to be due to reduction of apparent clearance in these patients. Ribavirin concentrations are essentially unchanged by haemodialysis.

Hepatic function: Single-dose pharmacokinetics of ribavirin in patients with mild, moderate or severe hepatic dysfunction (Child-Pugh Classification A, B or C) are similar to those of normal controls.

Elderly patients ($\geq 65$ years of age): Specific pharmacokinetic evaluations for elderly subjects have not been performed. However, in a population pharmacokinetic study, age was not a key factor in the kinetics of ribavirin; renal function is the determining factor.

Population pharmacokinetic analysis was performed using sparsely sampled serum concentration values from four controlled clinical trials. The clearance model developed showed that body weight, gender, age, and serum creatinine were the main covariates. For males, clearance was approximately 20% higher than for females. Clearance increased as a function of body weight and was reduced at ages greater than 40 years. Effects of these covariates on ribavirin clearance appear to be of limited clinical significance due to the substantial residual variability not accounted for by the model.

Children and adolescents: Ribavirin in combination with peginterferon alfa-2b
Multiple-dose pharmacokinetic properties for ribavirin and peginterferon alfa-2b in children and adolescent patients with chronic hepatitis C have been evaluated during a clinical study. In children and adolescent patients receiving body surface area-adjusted dosing of peginterferon alfa-2b at 60 microgram/m²/week, the log transformed ratio estimate of exposure during the dosing interval is predicted to be 58% (90% CI: 141 - 177%) higher than observed in adults receiving 1.5 microgram/kg/week. The pharmacokinetics of ribavirin (dose-normalized) in this trial were similar to those reported in a prior study of ribavirin in combination with interferon alfa-2b in children and adolescent patients and in adult patients.

**Ribavirin in combination with interferon alfa-2b**

Multiple-dose pharmacokinetic properties for ribavirin capsules and interferon alfa-2b in children and adolescents with chronic hepatitis C between 5 and 16 years of age are summarized in Table 14. The pharmacokinetics of ribavirin and interferon alfa-2b (dose-normalized) are similar in adults and children or adolescents.

**Table 14** Mean (% CV) multiple-dose pharmacokinetic parameters for interferon alfa-2b and ribavirin capsules when administered to children or adolescents with chronic hepatitis C

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Ribavirin 15 mg/kg/day as 2 divided doses (n = 17)</th>
<th>Interferon alfa-2b 3 MIU/m² 3 times a week (n = 54)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tmax (hr)</td>
<td>1.9 (83)</td>
<td>5.9 (36)</td>
</tr>
<tr>
<td>Cmax (ng/ml)</td>
<td>3,275 (25)</td>
<td>51 (48)</td>
</tr>
<tr>
<td>AUC*</td>
<td>29,774 (26)</td>
<td>622 (48)</td>
</tr>
<tr>
<td>Apparent clearance l/hr/kg</td>
<td>0.27 (27)</td>
<td>Not done</td>
</tr>
</tbody>
</table>

*AUC12 (ng.hr/ml) for ribavirin; AUC0-24 (IU.hr/ml) for interferon alfa-2b

**5.3 Preclinical safety data**

**Ribavirin**: Ribavirin is embryotoxic or teratogenic, or both, at doses well below the recommended human dose in all animal species in which studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with escalation of the dose. Survival of foetuses and offspring was reduced.

In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length. At the end of the recovery period, tibial and femoral changes were minimal although generally statistically significant compared to controls in males at all dose levels and in females dosed with the two highest doses compared to controls. No histopathological effects on bone were observed. No ribavirin effects were observed regarding neurobehavioural or reproductive development. Plasma concentrations achieved in rat pups were below human plasma concentrations at the therapeutic dose.

Erythrocytes are a primary target of toxicity for ribavirin in animal studies. Anaemia occurs shortly after initiation of dosing, but is rapidly reversible upon cessation of treatment.

In 3- and 6-month studies in mice to investigate ribavirin-induced testicular and sperm effects, abnormalities in sperm, occurred at doses of 15 mg/kg and above. These doses in animals produce systemic exposures well below those achieved in humans at therapeutic doses. Upon cessation of treatment, essentially total recovery from ribavirin-induced testicular toxicity occurred within one or two spermatogenic cycles (see section 4.6).

Genotoxicity studies have demonstrated that ribavirin does exert some genotoxic activity. Ribavirin was active in the Balb/3T3 in vitro Transformation Assay. Genotoxic activity was observed in the mouse lymphoma assay, and at doses of 20-200 mg/kg in a mouse micronucleus assay. A dominant lethal assay in rats was negative, indicating that if mutations occurred in rats they were not transmitted through male gametes.

Conventional carcinogenicity rodent studies with low exposures compared to human exposure under therapeutic conditions (factor 0.1 in rats and 1 in mice) did not reveal tumorigenicity of ribavirin. In addition, in a 26 week carcinogenicity study using the heterozygous p53(+/-) mouse model, ribavirin did not produce tumours at the maximally tolerated dose of 300 mg/kg (plasma exposure factor...
approximately 2.5 compared to human exposure). These studies suggest that a carcinogenic potential of ribavirin in humans is unlikely.

Ribavirin plus interferon: When used in combination with peginterferon alfa-2b or interferon alfa-2b, ribavirin did not cause any effects not previously seen with either active substance alone. The major treatment-related change was a reversible mild to moderate anaemia, the severity of which was greater than that produced by either active substance alone.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule contents:
Microcrystalline cellulose,
Lactose monohydrate,
Povidone K30
Magnesium stearate.

Capsule shell:
Gelatine,
Titanium dioxide,
Sodium lauryl sulphate.

Capsule imprint:
Shellac,
Propylene glycol,
Black iron oxide (E 172),
Strong ammonia solution,
Potassium hydroxide.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 30°C.

Blisters: Store in the original packaging.
HDPE bottles: Store in the original container.

6.5 Nature and contents of container

Ribavirin 200mg Capsules are available in PVC/PE/PVDC/Aluminium blisters and HDPE containers in the pack sizes of:

- PVC/PE/PVDC/aluminium blister: 14, 28, 42, 84, 112, 140 and 168 capsules
- HDPE bottle: 14, 28, 42, 84, 112, 140, 168 and 500 capsules

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Winthrop Pharmaceuticals UK limited
One Onslow Street
Guildford
Surrey
GU1 4YS, UK

Trading as: Winthrop Pharmaceuticals, PO Box 611, Guildford, Surrey, GU1 4YS, UK
<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>MARKETING AUTHORISATION NUMBER(S)</td>
<td>PL 17780/0439</td>
</tr>
<tr>
<td>9</td>
<td>DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</td>
<td>07/10/2011</td>
</tr>
<tr>
<td>10</td>
<td>DATE OF REVISION OF THE TEXT</td>
<td>07/10/2011</td>
</tr>
</tbody>
</table>
Module 3
Patient Information Leaflet

Please note that there is no mock-up available. The marketing authorisation holder has stated that it is not intending to market the product and, thus, no UK-specific documents have been submitted. The marketing authorisation holder has committed to submit the UK PIL for review to the regulatory authority before marketing the product.

PACKAGE LEAFLET: INFORMATION FOR THE USER

Ribavirin 200mg Capsules
ribavirin

Read all of this leaflet carefully before you start taking this medicine.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:
1. What ribavirin is and what it is used for
2. Before you take ribavirin
3. How to take ribavirin
4. Possible side effects
5. How to store ribavirin
6. Further information

1. WHAT RIBAVIRIN IS AND WHAT IT IS USED FOR

Ribavirin 200mg Capsules contain the active ingredient ribavirin. Ribavirin 200mg Capsules (referred to as ribavirin throughout this leaflet) is an antiviral medication. It is used to stop the multiplication of many types of viruses, including hepatitis C virus. Ribavirin must not be used alone. It must be used together with peginterferon alfa-2b or interferon alfa-2b.

Important
You should also carefully read all sections of the Package Leaflet for peginterferon alfa-2b or interferon alfa-2b before you begin combination treatment with ribavirin.

Previously untreated patients
The combination of ribavirin with peginterferon alfa-2b or interferon alfa-2b is used to treat patients 3 years of age and older who have chronic hepatitis C (HCV) infection.

The combination of ribavirin with peginterferon alfa-2b is also used to treat patients 18 years of age or older who have chronic hepatitis C, including patients who are co-infected with clinically stable HIV.

Previously treated adult patients
The combination of ribavirin with interferon alfa-2b is used to treat adult patients with chronic hepatitis C, who have previously responded to a treatment with an alpha interferon alone, but whose condition has returned.

The combination therapy of ribavirin with peginterferon alfa-2b is used to treat adult patients with chronic hepatitis C who have previously responded to treatment with an alpha interferon (pegylated or non-pegylated), alone or in combination therapy with ribavirin, but whose condition has returned.

The combination therapy of ribavirin with peginterferon alfa-2b is used to treat adult patients with chronic hepatitis C who have not responded to previous treatment with an alpha interferon (pegylated or non-pegylated), alone or in combination therapy with ribavirin.
There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e., not alfa 2b).

2. BEFORE YOU TAKE RIBAVIRIN

Do not take ribavirin
Tell your doctor if any of the following apply to you or the child you are caring for:

- you are allergic (hypersensitive) to ribavirin or any of the other ingredients of ribavirin (listed in Section 6)
- you are pregnant or planning to become pregnant (see section "Pregnancy and breast-feeding").
- you are breast-feeding.
- you had a problem with your heart during the past 6 months.
- you have a severe illness that leaves you feeling very weak
- you have severe kidney disease and/or are on haemodialysis.
- you have a serious problem with your liver other than chronic hepatitis C.
- you have any blood disorders, such as anaemia (low blood count), thalassemia, sickle-cell anaemia.
- you have autoimmune hepatitis or any other problem with your immune system.
- you are taking medicines that suppress your immune system (that protects you against infection and some diseases).

Use in Children and Adolescents
Ribavirin is not recommended for use in patients under the age of 3 years.

Children and adolescents weighing less than 47 kg:
The use of ribavirin is not recommended. Your doctor will advise you about other pediatric formulations intended for use in children 3 years of age and older and adolescents weighing less than 47 kg.

Children and adolescents must not take combination therapy with ribavirin and alpha interferon when there is existence or history of serious nervous or mental problems, such as severe depression, thoughts of suicide or attempted suicide.

Take special care with and check with your doctor before taking ribavirin
Talk with your doctor before you take ribavirin if:

- you are an adult who has or had a severe nervous or mental disorder, confusion, unconsciousness, or have had thoughts of suicide or have attempted suicide.
- you have ever had depression or develop symptoms associated with depression (e.g. feeling of great sadness) while on treatment with ribavirin.
- you are a woman of childbearing age (see section "Pregnancy and breast-feeding").
- you are a male and your female partner is of childbearing age (see section "Pregnancy and breastfeeding").
- you have had a serious heart condition in the past or have heart disease.
- you are older than 65 years
- if you have problems with your kidneys.
- you have or have had any serious illness.
- you have thyroid problems.

Depression
Some people get depressed when taking ribavirin in combination treatment with an interferon, and in some cases have thoughts about threatening the life of others, suicidal
thoughts or aggressive behaviour (sometimes directed against others). Some patients have actually committed suicide. You may want to consider asking a family member or close friend to help you stay alert to signs of depression or changes in your behaviour. Children and adolescents are particularly prone to develop depression when being treated with ribavirin and interferon alpha. Immediately contact the doctor or seek emergency treatment if they display any unusual behavioural symptoms, feel depressed, or feel they want to harm themselves or others.

Dental hygiene
When taking ribavirin you should take special care with your dental hygiene. This is because gum disorders, which may have a damaging effect on your teeth, have been reported. You should brush your teeth thoroughly twice a day and have regular dental examinations. In addition, if you vomit you should rinse your mouth thoroughly afterwards.

Eye problems
You should have an eye examination before you start and periodically during your treatment with ribavirin. This is because ribavirin can lead to eye problems or a worsening of existing eye problems. If you experience any worsening of your vision during treatment tell your doctor immediately.

Taking other medicines
Please tell your doctor or pharmacist if you or the child you are caring for:

- are taking or have recently taken any other medicines, including medicines obtained without a prescription,
- are receiving azathioprine in combination with ribavirin and pegylated alpha interferons. You may be at an increased risk of developing severe blood disorders.
- are infected with both Human Immunodeficiency Virus (HIV-positive) and Hepatitis C Virus (HCV) and are being treated with an anti-HIV medicine. Taking ribavirin at the same as the following medicines may cause adverse reactions:
  - an alpha interferon and an anti-HIV medicine may increase the risk of lactic acidosis (the build up of acid in the body), liver failure, and blood abnormalities (and a reduction in the number of blood cells).
  - zidovudine or stavudine. It is not certain if ribavirin will change the way these medicines work. Therefore, your blood will be checked regularly to be sure that the HIV infection is not getting worse. If it gets worse, your doctor will decide whether or not your ribavirin treatment needs to be changed.
  - zidovudine and alpha interferons could increase the risk of developing anaemia (low number of red blood cells). Therefore the use of zidovudine and ribavirin in combination with alpha interferons is not recommended.
  - ribavirin and didanosine is not recommended due to the risk of lactic acidosis (a build-up of lactic acid in the body) and pancreatitis (inflammation of the pancreas)
  - stavudine should be avoided.
  - HAART (a type of HIV treatment). Patients with advanced liver disease receiving HAART may be at increased risk of worsening liver function. Adding treatment with an alpha interferon alone or in combination with ribavirin may increase the risk in these patients.

Taking ribavirin with food and drink
Ribavirin must be taken with food.

Pregnancy and breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine
If you are pregnant or breastfeeding, you must not take ribavirin, as it can be very damaging to your baby. You must stop breast-feeding before you start taking ribavirin.

Fertility
Both female and male patients must take special precautions in their sexual activity if there is any possibility for pregnancy to occur:

- **Girls or women** of childbearing age
  You must have a negative pregnancy test before treatment, each month during treatment, and for the 4 months after treatment with this medicine is stopped. This should be discussed with your doctor.

- **Men**
  Do not have sex with a pregnant woman unless you use a condom. This will lessen the possibility for ribavirin to be left in the woman's body.
  If your female partner is not pregnant now but is of childbearing age, she must be tested for pregnancy each month during your treatment and for the 7 months after your treatment has stopped.

You and your female partner must each use an effective form of contraception while you are taking ribavirin and for 7 months after you stop treatment. This should be discussed with your doctor (see section "Do not take ribavirin").

**Driving and using machines**
Ribavirin does not affect your ability to drive or use machines; however, medicines taken in combination with ribavirin (peginterferon alfa-2b or interferon alfa-2b) may. Therefore, do not drive or use machines if you become tired, sleepy, or confused from this treatment.

**Important information about some of the ingredients of ribavirin**
Ribavirin capsules contain a small amount of lactose, a type of sugar. If you have been told by your doctor that you cannot tolerate some sugars, talk to your doctor before having this medicine.

### 3. HOW TO TAKE RIBAVIRIN

Always take ribavirin exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

- Do not take more than the recommended dose and take this medicine for as long as prescribed.
- Your doctor will determine the correct dose for you based on how much you, or the child you are caring for, weighs.
- Do not give this medicine to children under 3 years old.

**Standard blood tests** will be taken to check your blood, kidney and liver function.
- Blood tests will be done regularly to help your doctor to know if this treatment is working.
- Depending upon the results of these tests, your doctor may change the amount of ribavirin you need to take or the length of treatment.
- If you develop severe kidney or liver problems, this treatment will be stopped.

**Dosage**
The usual dose, according to how much the patient weighs, is shown in the table below. If your doctor's instructions are different from the table, follow your doctor's instructions.

<table>
<thead>
<tr>
<th>Ribavirin for oral use. Dose is based on body weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult weight</td>
</tr>
<tr>
<td>--------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Child/Adolescent weight</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>Less than 65 kg</td>
</tr>
<tr>
<td>65 – 80 kg</td>
</tr>
<tr>
<td>81 – 105 kg</td>
</tr>
<tr>
<td>More than 105 kg</td>
</tr>
</tbody>
</table>

Take your capsules by mouth with water and during your meal. Do not chew the capsules.

Interferon medicine that is used in combination with ribavirin may cause unusual tiredness. If you are injecting interferon yourself or giving it to a child, use it at bedtime.

**If you take more ribavirin than you should**
If you take more capsules than prescribed, tell a doctor or go to a hospital casualty department immediately. Take the medicine pack with you. This is so the doctor knows what you have taken.

**If you forget to take ribavirin**
If you forget to take a dose at the right time, take the missed dose as soon as possible during the same day. If it is almost time for your next dose, skip the missed dose and continue to follow the dosing schedule as usual. If an entire day has passed and you have not taken your medicine check with your doctor. Do not take a double dose to make up for a forgotten dose.

**4. POSSIBLE SIDE EFFECTS**

Like all medicines, ribavirin used in combination with an alpha interferon product can cause side effects, although not everybody gets them. Although not all of these unwanted effects may occur, they may need medical attention if they do occur.

**Seek medical help immediately if you or the child you are caring for experience:**
- symptoms of a severe allergic reaction such as difficulty in breathing, wheezing or hives
- depression
- suicidal thoughts
- attempt suicide
- thoughts about threatening the life of others
- changes in your behaviour
- aggressive behaviour
- chest pain or persistent cough
- changes in the way your heart beats
- fainting
• confusion
• feelings of numbness or tingling
• trouble sleeping, thinking or concentrating
• severe stomach pain, black or tar-like stools, blood in stool or urine, lower back or side pain
• painful or difficult urination
• severe bleeding from your nose,
• fever or chills beginning after a few weeks of treatment,
• problems with your eyesight or hearing,
• severe skin rash or redness.
• dark, cloudy or abnormally coloured urine
• chest pain
• pain down left arm
• jaw pain
• loss of consciousness
• loss of use, drooping or loss of power of facial muscles
• loss of feeling sensation
• loss of vision.

Possible side effects listed below are grouped by frequency of occurrence:

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very common</td>
<td>affects more than 1 user in 10</td>
</tr>
<tr>
<td>Common</td>
<td>affects 1 to 10 users in 100</td>
</tr>
<tr>
<td>Uncommon</td>
<td>affects 1 to 10 users in 1,000</td>
</tr>
<tr>
<td>Rare</td>
<td>affects 1 to 10 users in 10,000</td>
</tr>
<tr>
<td>Very rare</td>
<td>affects less than 1 user in 10,000</td>
</tr>
<tr>
<td>Not known</td>
<td>frequency cannot be estimated from the available data</td>
</tr>
</tbody>
</table>

**ADULTS**

The following side effects have been reported with the combination of ribavirin and an alpha interferon product in adults:

**Very common** (affects more than 1 in every 10 people)
• decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in number of white blood cells (neutrophils) that makes you more susceptible to different infections,
• difficulty concentrating, feeling anxious or nervous, mood swings, feeling depressed or irritable, feeling tired, trouble falling asleep or staying asleep,
• cough, dry mouth, sore throat (pharyngitis)
• diarrhoea, dizziness, fever, flu-like symptoms, headache, nausea, shaking chills, virus infection, vomiting, weakness,
• loss of appetite, loss of weight, stomach pain,
• dry skin, irritation, hair loss, itching, muscle pain, muscle aches, pain in joints and muscles, rash.

**Common** (affects less than 1 in every 10 people)
• decrease in blood clotting cells called platelets that may result in easy bruising and spontaneous bleeding, decrease in certain white blood cells called lymphocytes that help fight infection, decrease in thyroid gland activity (which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms), excess of sugar or uric acid (as in gout) in the blood, low calcium level in the blood, severe anaemia,
• fungal or bacterial infections, crying, agitation, memory loss (amnesia), nervousness, abnormal behaviour, aggressive behaviour, anger, feeling confused, lack of interest, mental disorder, mood changes, unusual dreams, wanting to harm yourself, feeling
sleepy, trouble sleeping, lack of interest in sex or inability to perform, vertigo (spinning feeling),

- blurred or abnormal vision, eye irritation or pain or infection, dry or teary eyes, changes in your hearing or voice, ringing in ears, ear infection, earache, cold sores (herpes simplex), change in taste, taste loss, bleeding gums or sores in mouth, burning sensation on tongue, sore tongue, inflamed gums, migraine, respiratory infections, sinusitis, nose bleed, nonproductive cough, rapid or difficult breathing, stuffy or runny nose, thirst, tooth disorder,
- cardiac murmur (abnormal heart beat sounds), chest pain or discomfort, feeling faint, feeling unwell, flushing, increased sweating, heat intolerance and excessive sweating, low or high blood pressure, palpitations (pounding heart beat), rapid heart rate,
- bloating, constipation, indigestion, wind (flatulence), increased appetite, irritated colon, irritation of prostate gland, jaundice (yellow skin), loose stools, pain on the right side around your ribs, enlarged liver, stomach upset, frequent need to urimate, passing more urine than usual, urinary tract infection, abnormal urine,
- difficult, irregular, or no menstrual period, abnormally heavy and prolonged menstrual periods, painful menstruation, disorder of ovary or vagina, breast pain, erectile problem,
- abnormal hair texture, acne, arthritis, bruising, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), hives, increased or decreased sensitivity to touch, nail disorder, muscle spasms, numbness or tingling feeling, limb pain, pain at the site of injection, pain in joints, shaky hands, a skin condition (psoriasis), puffy or swollen hands and ankles, sensitivity to sunlight, rash with raised spotted lesions, redness of skin or skin disorder, swollen face, swollen glands (swollen lymph nodes), tense muscles, tumour (unspecified), unsteady when walking.

**Uncommon** (affects 1 in every 100 people)

- hearing or seeing images that are not present,
- heart attack, panic attack,
- allergic (hypersensitivity) reaction to the medication,
- inflammation of pancreas, pain in bone, diabetes mellitus,
- muscle weakness.

**Rare** (affects 1 in every 1,000 people)

- seizure (convulsions)
- pneumonia,
- rheumatoid arthritis, kidney problems,
- dark or bloody stools, intense abdominal pain
- sarcoidosis (a disease characterised by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands),
- skin rash caused by narrow or blocked blood vessels (vasculitis).

**Very rare** (affects less than 1 in every 10,000 people)

- suicide.

**Other** (Frequency not known)

- thoughts about threatening the life of others,
- excessive or unreasonable enthusiasm (mania),
- inflammation of the lining of the heart (pericarditis) a fluid collection that develops between the lining of the heart (pericardium) and the heart itself (pericardial effusion)

**CHILDREN AND ADOLESCENTS**
The following side effects have been reported with the combination of ribavirin and an interferon alfa-2b product in children and adolescents:
**Very common** (affects more than 1 in every 10 people)
- decreases in the number of red blood cells (that may cause fatigue, shortness of breath, dizziness), decrease in number of white blood cells (neutrophils) that make you more susceptible to different infections,
- decrease in thyroid gland activity (which may make you feel tired, depressed, increase your sensitivity to cold and other symptoms),
- feeling depressed or irritable, feeling sick to your stomach, feeling unwell, mood swings, feeling tired, trouble falling asleep or staying asleep, virus infection, weakness,
- diarrhoea, dizziness, fever, flu-like symptoms, headache, loss of or increase in appetite, loss of weight, decrease in the rate of growth (height and weight), pain on right side of ribs, sore throat (pharyngitis), shaking chills, stomach pain, being sick (vomiting),
- dry skin, hair loss, irritation, itching, muscle pain, muscle aches, pain in joints and muscles, rash.

**Common** (affects 1 in every 10 people)
- decrease in blood clotting cells called platelets (that may result in easy bruising and spontaneous bleeding),
- excess of triglycerides (a type of fat) in the blood, excess of uric acid (as in gout) in the blood, increase in thyroid gland activity (which may cause nervousness, heat intolerance and excessive sweating, weight loss, palpitation, tremors),
- agitation, anger, aggressive behaviour, behaviour disorder, difficulty concentrating, emotional instability, fainting, feeling anxious or nervous, feeling cold, feeling confused, feeling of restlessness, feeling sleepy, lack of interest or attention, mood changes, pain, poor quality sleep, sleepwalking, suicide attempt, trouble sleeping, unusual dreams, wanting to harm yourself,
- bacterial infections, common cold, fungal infections, abnormal vision, dry or teary eyes, ear infection, eye irritation or pain or infection, change in taste, changes in your voice, cold sores, coughing, inflamed gums, nose bleed, nose irritation, oral pain, sore throat (pharyngitis), rapid breathing, respiratory infections, scaling lips and clefts in the corners of the mouth, shortness of breath, sinusitis, sneezing, sores in mouth, sore tongue, stuffy or runny nose, throat pain, toothache, tooth abscess, tooth disorder, spinning feeling (vertigo), weakness,
- chest pain, flushing, pounding heart beat (palpitations), rapid heart rate,
- abnormal liver function,
- acid reflux, back pain, bedwetting, constipation, gastroesophageal or rectal disorder, incontinence, increased appetite, inflammation of the membrane of the stomach and intestine, stomach upset, loose stools,
- urination disorders, urinary tract infection,
- difficult, irregular, or no menstrual period, abnormally heavy and prolonged menstrual periods, disorder of vagina, inflammation of the vagina, testis pain, development of male body traits,
- acne, bruising, eczema (inflamed, red, itchy and dryness of the skin with possible oozing lesions), fingers and toes very sensitive to cold, increased or decreased sensitivity to touch, increased sweating, increase in muscle movement, tense muscle, limb pain, nail disorder, numbness or tingling feeling, pale skin, rash with raised spotted lesions, shaky hands, redness of skin or skin disorder, skin discolouration, skin sensitive to sunlight, skin wound, water retention, which may cause swollen arms or legs, swollen glands (swollen lymph nodes), tremor, tumour (unspecified).

**Uncommon** (affects less than 1 in every 100 people)
- abnormal behaviour, emotional disorder, fear, nightmare,
- bleeding of the mucous membrane that lines the inner surface of the eyelids, blurred vision, drowsiness, intolerance to light, itchy eyes, facial pain, inflamed gums,
- chest discomfort, difficult breathing, lung infection, nasal discomfort, pneumonia,
• wheezing,
• low blood pressure,
• enlarged liver,
• painful menstruation,
• itchy anal area (pinworms or ascarids), blistering rash (shingles), decreased sensitivity to touch, muscle twitching, pain in skin, paleness, peeling of skin, redness, swelling.

Growth and development (children and adolescents):
During the one year of treatment with ribavirin in combination with either peginterferon alfa-2b or interferon alfa-2b, some children and adolescents did not grow or gain weight as much as expected. Some children did not reach their projected height within 1 - 5 years after completing treatment.

Ribavirin in combination with an alpha interferon product may also cause:
• A condition where the body stops or reduces the production of red blood cells. This causes severe anaemia, including unusual tiredness and a lack of energy,
• delusions,
• upper and lower respiratory tract infection,
• inflammation of the pancreas,
• severe rashes which may be associated with blisters in the mouth, nose, eyes and other mucosal membranes (erythema multiforme, Stevens Johnson syndrome)
• blistering and peeling of the top layer of skin (toxic epidermal necrolysis)
• abnormal thoughts, hearing or seeing images that are not present, altered mental status, disorientation,
• swelling of the hands, feet, ankles, face, lips, mouth, or throat which may cause difficulty in swallowing or breathing (angioedema), stroke (cerebrovascular events),
• an autoimmune inflammatory disorder affecting the eyes, skin and the membranes of the ears, brain and spinal cord (Vogt-Koyanagi-Harada syndrome)
• a severe, whole-body allergic reaction (bronchoconstriction and anaphylaxis), constant cough,
• eye problems including damage to the retina, obstruction of the retinal artery, inflammation of the optic nerve, swelling of the eye and cotton wool spots (white deposits on the retina),
• enlarged abdominal area, heartburn, trouble having bowel movement or painful bowel movement,
• acute hypersensitivity reactions including: hives (urticaria), bruises, intense pain in a limb, leg or thigh pain, loss of range of motion, stiffness, sarcoidosis (a disease characterised by persistent fever, weight loss, joint pain and swelling, skin lesions and swollen glands).

Adults co-infected with HCV/HIV and receiving anti-HIV treatment
If you are an HCV/HIV co-infected adult patient receiving anti-HIV treatment, the addition of ribavirin and peginterferon alfa-2b may increase your risk of:
• worsening liver function,
• lactic acidosis,
• liver failure
• developing blood abnormalities

Adults co-infected with HCV/HIV and receiving HAART
In HCV/HIV co-infected patients receiving HAART (a type of HIV treatment), the following other side effects have occurred with the combination of ribavirin and peginterferon alfa-2b (not listed above in adults side effects):
• decreased appetite,
• back pain,
• decreased white blood cells (CD4 lymphocytes),
• defective metabolism of fat,
• liver problems (hepatitis),
• limb pain,
• oral thrush (oral candidiasis),
• various laboratory blood values abnormalities.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE RIBAVIRIN

Keep out of the reach and sight of children.

Do not store above 30° C.
Store in the original packaging (blisters) or in the original container (bottles).

Do not use ribavirin after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of that month.

Do not use ribavirin 200mg Capsules without advice of your doctor or pharmacist if you notice any change in the appearance of the hard capsules.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6. FURTHER INFORMATION

What ribavirin contains
• The active substance is ribavirin. Each capsule contains 200 mg of ribavirin.
• The other ingredients are microcrystalline cellulose, lactose monohydrate (45 mg), povidone K30, magnesium stearate. The capsule shell contains gelatine, titanium dioxide, sodium lauryl sulphate. The capsule shell imprint contains shellac, propylene glycol, strong ammonia solution, black iron oxide (E 172) and potassium hydroxide.

What ribavirin looks like and contents of the pack
Ribavirin is a white capsule imprinted with ‘E’ on cap and ‘81’ on body in black ink.

Ribavirin is available in blister packs containing 14, 28, 42, 84, 112, 140 or 168 capsules or bottles containing 14, 28, 42, 84, 112, 140, 168 or 500 capsules.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder:
Winthrop Pharmaceuticals,
PO Box 611,
Guildford,
Surrey,
GU1 4YS, UK
Manufacturer:
Winthrop Pharmaceuticals
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far,
Birzebbugia, BBG 3000.
Malta

For Germany:
Winthrop Arzneimittel GmbH
Urmitzer Str. 5
D-56218 Mülheim-Kärlich
Germany

This leaflet was last revised in September 2011.
Module 4
Labelling

Please note that there is no mock-up available. The marketing authorisation holder has stated that it is not intending to market the product and, thus, no UK-specific documents have been submitted. The marketing authorisation holder has committed to submit the UK labelling for review to the regulatory authority before marketing the product.

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

| RIBAVIRIN 200MG CAPSULES – 14, 28, 42, 84, 112, 140, 168 hard capsules |
| Outer packaging for blisters |

1. **NAME OF THE MEDICINAL PRODUCT**

RIBAVIRIN 200MG CAPSULES
Ribavirin

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each capsule contains 200 mg of ribavirin.

3. **LIST OF EXCIPIENTS**

Contains lactose.

4. **PHARMACEUTICAL FORM AND CONTENTS**

14 hard capsules
28 hard capsules
42 hard capsules
84 hard capsules
112 hard capsules
140 hard capsules
168 hard capsules

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Oral use
Read the package leaflet before use.

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN**

Keep out of the reach and sight of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

N/A
8. EXPIRY DATE

EXP:

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original packaging.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

N/A

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Winthrop Pharmaceuticals, PO Box 611, GU1 4YS, UK

12. MARKETING AUTHORISATION NUMBER(S)

PL 17780/0439

13. BATCH NUMBER

Batch:

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

Use as directed by medical practitioner.

16. INFORMATION IN BRAILLE

Ribavirin 200mg Capsules
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

RIBAVIRIN 200MG CAPSULES – 14, 28, 42, 84, 112, 140, 168, 500 hard capsules
(Outer packaging for bottle)

1. NAME OF THE MEDICINAL PRODUCT

RIBAVIRIN 200MG CAPSULES
Ribavirin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each capsule contains 200 mg of ribavirin.

3. LIST OF EXCIPIENTS

Contains lactose.

4. PHARMACEUTICAL FORM AND CONTENTS

14 hard capsules
28 hard capsules
42 hard capsules
84 hard capsules
112 hard capsules
140 hard capsules
168 hard capsules
500 hard capsules

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

N/A
8. EXPIRY DATE

EXP:

9. SPECIAL STORAGE CONDITIONS

Do not store above 30° C.
Store in the original container.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

N/A

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Winthrop Pharmaceuticals, PO Box 611, GU1 4YS, UK

12. MARKETING AUTHORISATION NUMBER(S)

PL 17780/0439

13. BATCH NUMBER

Batch:

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription

15. INSTRUCTIONS ON USE

Use as directed by medical practitioner.

16. INFORMATION IN BRAILLE

Ribavirin 200mg Capsules
MINIMUM PARTICULARS TO APPEAR ON BLISTERS

RIBAVIRIN 200MG CAPSULES – 14, 28, 42, 84, 112, 140, 168 hard capsules

1. NAME OF THE MEDICINAL PRODUCT

RIBAVIRIN 200MG CAPSULES
Ribavirin

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Winthrop Pharmaceuticals

3. EXPIRY DATE

EXP:

4. BATCH NUMBER

Batch:

5. OTHER
1. NAME OF THE MEDICINAL PRODUCT

RIBAVIRIN 200MG CAPSULES
Ribavirin

2. METHOD OF ADMINISTRATION

Oral use

3. EXPIRY DATE

EXP:

4. BATCH NUMBER

Batch:

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

14 hard capsules
28 hard capsules
42 hard capsules

6. OTHER

Do not store above 30°C.
Store in the original container.
Winthrop Pharmaceuticals
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING

RIBAVIRIN 200MG CAPSULES – 84, 112, 140, 168, 500 hard capsules (HDPE bottle)

1. NAME OF THE MEDICINAL PRODUCT

RIBAVIRIN 200MG CAPSULES
Ribavirin

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each capsule contains 200 mg of ribavirin.

3. LIST OF EXCIPIENTS

Contains lactose.

4. PHARMACEUTICAL FORM AND CONTENTS

84 hard capsules
112 hard capsules
140 hard capsules
168 hard capsules
500 hard capsules

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

N/A
8. EXPIRY DATE

EXP:

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C.
Store in the original packaging.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

N/A

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Winthrop Pharmaceuticals, PO Box 611, GU1 4YS, UK

12. MARKETING AUTHORISATION NUMBER(S)

PL 17780/0439

13. BATCH NUMBER

Batch:
Module 5
Scientific discussion during initial procedure

I INTRODUCTION
Based on the review of the data on quality, safety and efficacy, Germany, France and the UK considered that the application for Ribavirin 200mg Capsules could be approved. This prescription only medicine (POM) is indicated for for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Ribavirin 200mg Capsules monotherapy must not be used.

There is no safety or efficacy information on the use of Ribavirin 200mg Capsules with other forms of interferon (i.e. not alfa-2b).

This application for Ribavirin 200mg Capsules was submitted according to Article 10.1 of Directive 2001/83/EC, claiming to be a generic medicinal product of Rebetol 200mg Hard Capsules, first authorised in the EEA in 1999 to Shering Plough Europe. This product was centrally authorised in all EEA member states.

Ribavirin is a synthetic nucleoside analogue which has shown in vitro activity against some RNA and DNA viruses. The mechanism by which ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b exerts its effects against HCV is unknown.

No new non-clinical studies were conducted, which is acceptable given that the product contains a widely-used, well-known active substance. No clinical studies, with the exception of the bioequivalence study, have been performed and none are required for this application as the pharmacology of ribavirin is well-established.

For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites.

For manufacturing sites outside the community, the RMS has accepted copies of current GMP Certificates or satisfactory inspection summary reports, ‘close-out letters’ or ‘exchange of information’ issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-Community sites.

The RMS considers that the pharmacovigilance system as described by the applicant fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

A satisfactory justification has been provided for the absence of a Risk Management Plan.
## II. ABOUT THE PRODUCT

<table>
<thead>
<tr>
<th>Name of the product in the Reference Member State</th>
<th>Ribavirin 200mg Capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name(s) of the active substance(s) (INN)</td>
<td>Ribavirin</td>
</tr>
<tr>
<td>Pharmacotherapeutic classification (ATC code)</td>
<td>Direct acting antivirals, nucleosides and nucleotides (excl. reverse transcriptase inhibitors) (J05A B04)</td>
</tr>
<tr>
<td>Pharmaceutical form and strength(s)</td>
<td>200mg capsules</td>
</tr>
<tr>
<td>Reference numbers for the Decentralised Procedure</td>
<td>UK/H/3127/001/DC</td>
</tr>
<tr>
<td>Reference Member State</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member States concerned</td>
<td>Germany (DE), France (FR)</td>
</tr>
<tr>
<td>Marketing Authorisation Number(s)</td>
<td>PL 17780/0439</td>
</tr>
<tr>
<td>Name and address of the authorisation holder</td>
<td>Winthrop Pharmaceuticals UK limited One Onslow Street Guildford Surrey GU1 4YS United Kingdom</td>
</tr>
</tbody>
</table>
III  SCIENTIFIC OVERVIEW AND DISCUSSION

III.1  QUALITY ASPECTS

S.  Active substance

INN name:  Ribavirin
Chemical name:  1-β-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide

Structural formula:

![Structural formula of Ribavirin]

Molecular formula:  \( \text{C}_8\text{H}_{12}\text{N}_4\text{O}_5 \)

Appearance:  White crystalline powder.

Molecular weight:  244.2

Solubility:  Freely soluble in water, practically insoluble in ethanol (96%) and in methylene chloride.

Ribavirin complies with its European Pharmacopoeia monograph.

All aspects of the manufacture of the active substance from its starting materials are controlled by a Certificate of Suitability.

All potential known impurities have been identified and characterised.

An appropriate specification with suitable test methods and limits is provided for the active substance. The methods of testing and limits for residual solvents are in compliance with current guidelines. Suitable Certificates of Analysis have been provided for all reference and impurity standards used. Batch analysis data are provided and comply with the proposed specification.

Stability studies have been performed with the drug substance and no significant changes of the parameters were observed. On the basis of the results, the RMS agreed that a suitable re-test period could be approved.

P.  Medicinal Product

Other Ingredients

Other ingredients in the capsule core consist of the pharmaceutical excipients microcrystalline cellulose, lactose monohydrate, povidone K30 and magnesium stearate.

The ingredients in the capsule shell are gelatin, titanium dioxide and sodium lauryl sulphate.

The ingredients in the capsule imprint are shellac, propylene glycol, black iron oxide (E 172), strong ammonia solution and potassium hydroxide.
With the exception of shellac, propylene glycol, strong ammonia solution, black iron oxide (E 172) and potassium hydroxide, all excipients comply with their respective European Pharmacopoeia monographs. Shellac, strong ammonia solution, black iron oxide (E 172) and potassium hydroxide all comply with the National Formulary. Propylene glycol complies with the United States Pharmacopoeia.

None of the excipients used contain material of human origin. The suppliers of the excipients have provided declarations that neither the excipients nor any material used in the production of the excipients pose a transmissible spongiform encephalopathies (TSE) risk. The supplier of gelatin has provided valid TSE Certificates of Suitability.

No genetically modified organisms (GMO) have been used in the preparation of this product.

**Pharmaceutical Development**
The objective of the development programme was to produce a safe, efficacious product containing ribavirin that could be considered a generic medicinal product of Rebetol 200mg Hard Capsules.

The applicant has provided suitable product development information. Justifications for the use and amounts of each excipient have been provided and are valid.

Comparative *in vitro* assay, impurity and dissolution profiles have been provided for the proposed and reference product.

**Manufacturing Process**
A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results. Satisfactory process validation data on batches have been provided. The applicant has committed to perform process validation on future commercial-scale batches.

**Finished Product Specification**
The finished product specification is acceptable. Test methods have been described and adequately validated, as appropriate. Batch data have been provided and comply with the release specifications. Certificates of Analysis have been provided for any working standards used.

**Container-Closure System**
This product is packaged in:

i) blister composed of polyvinyl chloride (PVC), polyethylene (PE), polyvinylidene chloride (PVDC) and aluminium

ii) high density polyethylene (HDPE) containers

Pack sizes are:
Blister: 14, 28, 42, 84, 112, 140 and 168 capsules
HDPE bottles: 14, 28, 42, 84, 112, 140, 168 and 500 capsules

Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary product packaging complies with EU legislation.
Stability of the product
Stability studies were performed on batches of the finished products in the packaging proposed for marketing and in accordance with current guidelines. These data support a shelf-life of 3 years with the following storage instructions:
‘Do not store above 30° C’
And for the relevant containers:
‘Blisters: Store in the original packaging.
HDPE bottles: Store in the original container.’
This is satisfactory.

Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), Labels
The SmPC, PIL and labelling are pharmaceutically acceptable. A representative sample of the UK PIL and label texts are included in modules 3 and 4 of this report.

User testing results have been submitted for the PIL for this product. The results indicate that the PIL is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

MAA form
The MAA form is pharmaceutically satisfactory.

Expert report
The pharmaceutical expert report has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical dossier.

Conclusion
It is recommended that a Marketing Authorisation is granted for this application from a quality point of view.
III.2 NON-CLINICAL ASPECTS

The pharmacodynamics, pharmacokinetics and toxicological properties of ribavirin are well-known. As ribavirin is a widely used, well-known active substance, the applicant has not provided any new non-clinical data and none are required. An overview based on literature review is, thus, appropriate.

The proposed limits for the impurities from the drug substance and drug product specification were found to comply with current international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) guidelines.

The non-clinical expert report has been written by an appropriately qualified person and is a suitable summary of the non-clinical aspects of the dossier.

A satisfactory justification has been provided for the absence of an Environmental Risk Assessment.

It is recommended that a Marketing Authorisation is granted for this application from a non-clinical point of view.
III.3 CLINICAL ASPECTS
CLINICAL PHARMACOLOGY

With the exception of the following bioequivalence study, no new pharmacokinetic or pharmacodynamic data were submitted with this application and none were required.

Pharmacokinetics
A single dose randomised, two-sequence, two-period, crossover study to compare the pharmacokinetics of the test product Ribavirin 200mg Capsules versus the reference product Rebetol (ribavirin) 200mg Capsules (Schering Plough Europe) in healthy subjects under fed conditions.

Blood samples were taken pre- and up to 48 hours post dose. There was a washout period of at least 35 days between each treatment period. Pharmacokinetic parameters were measured from the plasma and statistically analysed.

Results for ribavirin are presented below as log-transformed values:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>AUC0-t (hr.ng/mL)</th>
<th>AUC0-∞ (hr.ng/mL)</th>
<th>Cmax (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test (T)</td>
<td>9086.89</td>
<td>12740.25</td>
<td>521.77</td>
</tr>
<tr>
<td>Reference (R)</td>
<td>9250.50</td>
<td>12626.95</td>
<td>497.86</td>
</tr>
<tr>
<td>T/R Ratio (90% CI)</td>
<td>98.23</td>
<td>100.90</td>
<td>104.80</td>
</tr>
<tr>
<td></td>
<td>88.75 – 108.73</td>
<td>84.66 – 120.25</td>
<td>97.58 – 112.56</td>
</tr>
</tbody>
</table>

The results for the primary variables indicated that the 90% confidence intervals test/reference ratio of geometric means for AUC0-t, AUC0-∞ and Cmax for ribavirin lie within the acceptance criteria of 80-125%. Thus, bioequivalence has been shown between the test and reference products in this study.

EFFICACY
No new efficacy data were submitted with this application and none were required.

SAFETY
With the exception of the data submitted during the bioequivalence study, no new safety data were submitted with this application and none were required. No new or unexpected safety concerns were raised during the bioequivalence study.

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC), PATIENT INFORMATION LEAFLET (PIL) AND LABELLING
The SmPC, PIL and labelling are clinically satisfactory and consistent with those for the reference product.

CLINICAL EXPERT REPORT
The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier.
MAA FORM
The MAA form is clinically satisfactory.

CONCLUSIONS
It is recommended that a Marketing Authorisation is granted for this application from a clinical point of view.
IV OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT
QUALITY
The important quality characteristics of Ribavirin 200mg Capsules are well defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit-risk balance.

NON-CLINICAL
No new non-clinical data were submitted and none are required for an application of this type.

EFFICACY
Bioequivalence has been demonstrated between the applicant’s Ribavirin 200mg Capsules and the reference product Rebetol 200mg Hard Capsules.

No new or unexpected safety concerns arise from this application.

The SmPC, PIL and labelling are satisfactory and consistent with that for the reference product.

BENEFIT-RISK ASSESSMENT
The quality of the product is acceptable and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with ribavirin is considered to have demonstrated the therapeutic value of the compound. The benefit-risk is, therefore, considered to be positive.
Module 6

**STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY**

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>